

May 31, 2024

CURRICULUM VITAE

GENE GARRARD OLINGER JR., PH.D., M.B.A

PRESENT POSITION AND EMPLOYER'S PHYSICAL ADDRESS:

DEPUTY DIRECTOR 2024-present
Galveston National Laboratory, University of Texas Medical Branch
Galveston, Texas, USA

ASSISTANT PROFESSOR 2024-present
Department of Microbiology
University of Texas Medical Branch
Galveston, Texas, USA

PROFESSOR 2019-present
Kansas City University Biomedical Sciences
Kansas City, Missouri, USA

Distinguished Research Fellow (~10%) 03/2024- present
MRIGlobal, Inc
Kansas City, MO

CO-FOUNDER & CHIEF SCIENCE OFFICER 2022-present
Oyanalytika, Inc.
Frederick, Maryland, USA

SCIENCE ADVISOR 2021-present
The Life Sciences Division
London, UK

CONTACT INFORMATION:

Phone: 240-344-0847
Email: ggolinge@utmb.edu; garrard113@aol.com

UNIVERSITY EDUCATION:

RUSH UNIVERSITY MEDICAL CENTER 06/2001
Chicago, IL
Doctor of Philosophy (PhD), Immunology & Microbiology

MOUNT ST. MARY'S UNIVERSITY 05/2006
Emmitsburg, MD
Master of Business Administration (MBA), Business Organization

OLD DOMINION UNIVERSITY 05/1993
Norfolk, VA
Bachelor of Science (BS), Environmental Health & Biology

CERTIFICATIONS:

DEPARTMENT OF DEFENSE EDUCATION ACTIVITY Executive Leadership Development Program	2010
MASSACHUSETTS INSTITUTE OF TECHNOLOGY Sloan School of Management Boston, MA Executive Certificate in Management & Leadership	2009
DEFENSE ACQUISITION UNIVERSITY Level III Certification for a Science and Technology Manager	2008
NATIONAL ENVIRONMENTAL HEALTH ASSOCIATION Registered Environmental Health Specialist	1993

CLEARANCES:

CDC Select Agent Clearance

Clearances obtained (TS/SCI/POLY)

PROFESSIONAL WORK HISTORY AND TEACHING EXPERIENCE:

CHIEF SCIENCE ADVISOR MRIGlobal, Inc Kansas City, MO	09/2021- 03/2024
ADJUNCT ASSOCIATE PROFESSOR OF MEDICINE Boston University Boston, MA	02/2010-02/2024
ASSOCIATE DIRECTOR: MAXIMUM CONTAINMENT TRAINING Environmental Health and Safety Boston University, National Emerging Infectious Diseases Laboratory (NEIDL), Boston, MA	02/2010-02/2024
ADJUNCT FACULTY, INSTRUCTOR Hood College, Biology, Ecology Sustainability Program Frederick, MD	08/2021-01/2024
SCIENTIFIC ADVISOR/HIGH CONTAINMENT COORDINATOR National Institute of Health (NIH) National Institute of Allergies and Infectious Diseases (NIAID) – Integrated Research Facility Fort Detrick, MD	09/2013-2016
PRINCIPAL INVESTIGATOR/SUPERVISORY MICROBIOLOGIST United States Army Medical Research Institute of Infectious Diseases Virology Division	09/2009-08/2013

Fort Detrick, MD

MANAGING MEMBER Dream Flight Aviation, LLC Frederick, MD	05/2004-Present
--	-----------------

MICROBIOLOGIST United States Army Medical Research Institute of Infectious Diseases Department of Host and Cell Responses & Vector Assessment Fort Detrick, MD	09/2004-09/2009
---	-----------------

POST-DOCTORAL FELLOW United States Army Medical Research Institute of Infectious Diseases National Research Council Fellowship Fort Detrick, MD	08/2001-09/2004
--	-----------------

GRADUATE STUDENT Rush University, Department of Immunology & Microbiology Chicago, IL	08/1996-06/2001
---	-----------------

SENIOR ENVIRONMENTAL HEALTH SPECIALIST Virginia Department of Health Chesapeake, VA	10/1993-08/1996
---	-----------------

RESEARCH ASSISTANT Old Dominion Research Foundation ODU Center for Biotechnology Norfolk, VA	06/1992-08/1996
---	-----------------

COMMISSIONED OFFICER STUDENT EXTERN Food and Drug Administration Center for Devices and Radiological Health Occupational Safety and Health U.S. Public Health Service Rockville, MD	05/1992-09/1992
---	-----------------

RESEARCH ACTIVITIES:

Area of Research: Infectious Diseases, Virology, Microbiology, Immunology, Vaccine and Therapeutic development

Grant support:

Current:

HHSN272201700001C - NIH/NIAID Mycobacterium Tuberculosis (MTB) Quality Assessment Program (TBQA) Support Role: Principal Investigator, 10% effort; \$21.9 million	2023 - 2030
---	-------------

Past:

IDIQ 12639521D0048 - USDA/APHIS	2021 - 2026
---------------------------------	-------------

NBAF Operation and Science Training Services
Role: Principal Investigator (ended 03/2024), 10% effort; \$11.1 million

HHSN75A50122D00018 – BARDA IDIQ 2021 - 2026
Biological Animal Model and MCM Development
Role: Principal Investigator (ended 03/2024), 10% effort; \$12.0 million

RPP-17-03 – JPEO-CBRND 2018 – 2025
An ultra-portable, easy-to-use device to provide early warning of suspected exposure to a chemical warfare nerve agent - *ChemDx*
Role: Design & Stage Reviewer (ended 03/2024), 3% effort; \$21.9 million

HR001121C0022 - DARPA 2021 - 2024
Research and Development in Biotechnology, Synthetic Biology/BTO Office
Role: Co-applicant, subcontract, 10% effort, \$12.8 million

HHSO100201700015I-75A50120F33002 RTOR BIO-AMT-1021 2020 - 2023
BARDA - Biological Development of Animal Models for Evaluation of Medical Countermeasures for SARS-CoV-2
Role: Principal Investigator, 10% effort; \$5.7 million

Bill and Melinda Gates Foundation - Global 2020 - 2023
Health Division To establish training modules for laboratory and data analytics work related to COVID-19 genomic epidemiology.
Role: Principal Investigator, 10% effort; \$249,836.00

HHSN272201700001C - NIH/NIAID 2020 - 2022
Mycobacterium Tuberculosis (MTB) Quality Assessment Program (TBQA) Support Program
Role: Principal Investigator, 10% effort; \$13.7 million

W911QY-15-D0023 –JPEO CBRND 2017 – 2021
Biomeme Fever Panel Development - Savannah Program
Role: Subject Matter Expert, 10% effort; total of \$2.3 million from

W911QY-15-D0023 – BARDA 2016 – 2021
Advanced Development for a qPCR based Quantitative Biodosimetry Assay for Radiation Exposure (Arad Biodosimetry Test) -Biodosimetry Radiation Mass Casualty Diagnostic Development
Role: Subject Matter Expert, Nonclinical Studies, 10% effort; \$16.0 million

5UC7AI095321-04; Application No. 9272312 – NIAID 2009 - 2021
National Biocontainment Laboratory Operations Cooperative Agreement (U7) Special Emphasis Panel ZAI1
PI: Dr. Ron Corley; \$11.5 million

Subcontract No. 60000520-1 to HHSN2722007000161NIH - NIAID 2007 - 2017
Staffing and operations of the NIH NIAID Integrated Research Facility (IRF)
Role: Chief Scientist; \$15.2 million

CBCALL12-VAXV2-2-0169 – DTRA 2012 - 2015

Long-term Sequelae and Immune Response to Ebola Virus Infection.
Role: Contracting Officer Representative and co-investigator; \$1.1 million

U01 AI061270-01 - NIH 2012 - 2015
An Ebola Virus Countermeasure: MB-2003 - Monoclonal Antibodies in Biodefense
Role: Co-Investigator/USAMRIID Site Study Director; \$200,000 per year

CBCALL12-THRFDA1-2-0135 – DTRA 2011 - 2015
Evaluation of FDA Approved Drugs against the Arenaviridae, Bunyaviridae,
Flaviviridae, Filoviridae, and Togaviridae.
Role: Co-Investigator/VHFV lead; \$3.3 million

CBCALL12-VAXV2-1-0756 – DTRA 2009 - 2014
Preclinical Development of the VEE Replicon Particle (VRP) Vaccine Candidate for
Filoviruses.
Role: Principal Investigator/Team lead, \$5.9 million/year.

UC7 AI070088 – NIH NIAID 2006 - 2013
National Emerging Infectious Diseases Laboratories Operations.
Role: Associate Director for High Containment Training; \$13.5 million.

CBCALL12-VAXV1-2-0145 – DTRA 2009 - 2011
BSL-2 VEE Assay Development: Development of a Non-Select Agent, Biosafety Level 2
In Vitro Neutralization Assay for Assessing Alphavirus Vaccination in Humans.
Role: Principal Investigator, \$498,000/year

As a government employee at USAMRIID, served as Investigator or Co-investigator on
multiple federally funded projects grants and contract projects including Cooperative
Research and Development Agreements (CRADAs) with federal agencies, industry,
academia, and NGOs that exceed \$29 million from 2001-2013.

COMMITTEE RESPONSIBILITIES:

International:

Joint Steering Committee Member for Ebola Diagnostics Response: Liberia, U.S.
Department of Defense, and NIH NIAID, LIBR Institute 2014 - 2016

Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL) -
Liberian and U.S. Partnership for Research 2014 - 2016

International Atomic Energy Agency (IAEA) Animal Production and Health Section
Joint FAO/IAEA Centre of Nuclear Techniques in Food and Agriculture 2022 - 2024

American Association for Accreditation of Laboratory Animal Care (AAALAC
International) ad hoc specialist 2017 –2026

H3D Delegates 3rd H3D Mentor Program – Scientific mentoring program for Post
doctoral and early scientists University of Cape Town 2021 - 2023

Medical Research Foundation for the Impact of Climate Change on Health 2023

R&D Blueprint and COVID WHO Working Group for viruses, reagents, and immune assays 2020-2023

R&D Blueprint and COVID WHO Working Group-Animal models in SARS-CoV-2 Research 2020-2023

National:

Engineering Biology Research Consortium (ERBC) Academic Member 2024 – present

COVID Vaccine Data Safety Monitoring Member: Multiple Committees 2023 - present

Ad hoc Consultant with the MARS Sample Return Facility Design Team 2023

Civil Air Patrol, Frederick, Maryland Squadron, 1st LT 2010-present

Engineering Biology for Space Health: An Innovative Research Roadmap ERBC and NASA Translational Research Institute for Space Health (TRISH) Experts Panel 2023 - 2024

Newsweek Forum Panel Member Vetted Cross Industry Senior Expert – Nominated 2023 - 2024

Engineering Biology Research Consortium (ERBC) Industry Member 2020 – 2024

1DaySOONER COVID 19 Human Clinical Challenge Trial Planning Committee 2021 - 2022

CDC Technical Advisor Program 1.0, Epidemiology and Laboratory Capacity 2021-2022

Civil Air Patrol, sUAS drone pilot, mission pilot, instructor, and check pilot 2019

ad Hoc technical maximum containment IACUC member for Boston University Medical School 2014-2016

Filovirus Animal Non-Clinical Group (FANG) committee member presenter 2011-2016

Vice Chair of the NIH NIAID Division of Clinical Research IRF Institutional Animal Care and Use Committee 2013 - 2016

Alternate Chair of the USAMRIID Institutional Animal Care and Use Committee 2005 - 2013

Filovirus Animal Non-Clinical Group (FANG) 2011 - 2016

The Technical Cooperation Program (TTCP) Tech Panel 4 (TP4) Medical Countermeasures for Biological Agents. U.S. DoD SME and participant 2005 - 2013

Ercoupe Owners Association, member and Regional Board of Director 2005 - 2013

ASV Program Committee for the Annual National Meeting 2007 - 2010

Department of Defense, Chemical and Biological Medical Systems Critical Reagents Program, CRP Reference Material IPT team, Virology SME	2008
NIH National Cancer Institute Protein Think Tank Member	2008
American Society of Virology Program Committee Member	2007 - 2008
Department of Health and Human Services (DHHS) Viral Hemorrhagic Fever Viruses (VHFV) Integrated Product Development Team (IPT) member	2007 - 2008
NIH/ NIAID Interagency Select Agent Review Group (ISARG)	2006

State/Regional:

Hood College Biomedical Science Master's Program Scientific Board	2024 - present
---	----------------

Other:

Scientific Sessions Organized:

"FIRST MOVERS" IN BIODETECTION: CASE COMPARISON ON HARNESSING SCIENCE, INDUSTRY, AND ENTREPRENEURSHIP TO DETECT HIGH CONSEQUENCE PATHOGENS ASM Biothreats Conference Panel Discussion	01/2021
11th ANNUAL KAIMRC GLOBAL FORUM G20 event entitled COVID-19 Vaccines: Global Challenges and Prospects Role: Co-organizer	11/2020
2020 MILITARY HEALTH SECURITY SUMMIT Cohosted by the Australian Defence Force and US Indo-PACOM at the University of Sydney and Global Health Security Agenda activities. Role: Co-organizer	05/2019
AMERICAN SOCIETY OF VIROLOGY Role: Convener of Filovirus panel section	07/2009

Scientific Sessions Chaired/ Discussion Leader:

LEVERAGING GEOSPATIAL TO ADDRESS HEALTH SECURITY AND COMPLEX THREAT ENVIRONMENTS WORKSHOP University of Missouri Role: Discussion leader and organizer	10/2022
DEFENSE ADVANCED RESEARCH PROJECT AGENCY (DARPA) / ACCELERATED MANUFACTURE OF PHARMACEUTICALS Role: ad hoc review panel member, meeting presenter	2009
DEFENSE ADVANCED RESEARCH PROJECT AGENCY (DARPA) / ARTIFICIAL IMMUNE SYSTEMS	2009

Role: ad hoc review panel member, meeting presenter

AMERICAN SOCIETY OF VIROLOGY 2008
Role: Workshop Reviewer for Vaccines and Vector Technologies

SCIENTIFIC CONFERENCE ON CHEMICAL & BIOLOGICAL DEFENSE
RESEARCH 11/2006
Role: Invited participant and speaker

Scientific Sessions Participant:

COVID-19 UPDATE PANEL TALK/Q&A Lolly Gardiner and Gene Olinger
KGNU Boulder/Denver National Public Radio 04/2020

UNITING THE LIFE SCIENCES COMMUNITY TO COMBAT COVID-19
Gene Olinger BioNexus 04/2020

CONVERGENCE OF HIGH CONSEQUENCE FOREIGN ANIMAL AND
HUMAN PATHOGEN RESEARCH: PARADOX OF ZOO NOTIC DISEASES
Gene Olinger ASM Biothreat Conference 02/2018

GLOBAL HEALTH SECURITY ISSUES Gene Olinger Frederick CREST,
Current Topics in Research 11/2018

EBOLA THERAPEUTICS AT THE START OF THE OUTBREAK 2014: THE
VALLEY OF DEATH Gene Olinger Canadian National Microbiology
Laboratory, Winnipeg CA & University of Manitoba Medical School 04/2018

EBOLA WHO THERAPEUTICS MEETING, EBOLA EMERGENCY,
SPECIAL SESSION 01/2015
Role: Delegate for NIH/NIAID IRF; Location: Geneva, Switzerland

IN VITRO EVALUATION OF REPURPOSED AND FAST TRACK DRUGS
FOR EVD: AN ACCELERATED DRUG DISCOVERY PIPELINE. WORLD
HEALTH ORGANIZATION (WHO) SCIENCE THERAPEUTIC ANTIVIRAL
COMMITTEE (STAC). 03/2015
Role: Invited participant and speaker; Location: Montreux, Switzerland.

DIAGNOSTICS, SEQUENCING AND EMERGING TECHNOLOGIES FOR
EBOLA VIRUS. WORLD HEALTH ORGANIZATION (WHO) EBOLA
SCIENCE COMMITTEE 03/2015
Role: Invited participant and speaker; Location: Montreux, Switzerland.

TEACHING AND MENTORING ACTIVITIES:

I. Teaching and Mentoring Responsibilities at USAMRIID:

a. Teaching: N/A

b. Mentoring:

Residents/post-doctoral fellows:

As National Research Council Post Doctoral Advisor from 2005-2013

08/2011 – 09/2013	Brian Friedrich, PhD
04/2009 – 08/2010	Andrew Herbert, PhD
03/2007 – 06/2010	Julia O'Hara Biggins, PhD
01/2009 – 01/2013	Jennifer M. Brannan, PhD
09/2007 – 02/2012	Corrine Zeitler, PhD

As Principal Supervisor

07/2010 – 09/2013	Jason Regules, MD
10/2008 – 09/2013	Venessa Melanson, PhD
04/2013 – 09/2013	Aileen Ohearn, PhD
10/2010 – 06/2013	Julia O'Hara Biggins, PhD

Ph. D Students:

As Principal Supervisor

02/2010 – 06/2015	Lauren Neighbors-Wilcoxon, PhD
-------------------	--------------------------------

Master's students:

As Principal Supervisor

04/2008 - 07/2015	Joshua Johnson, MS Hood College Bioscience
01/2009 - 09/2010	James Pettitt, MS Hood College Bioscience
09/2004 - 12/2006	Andrea Stossel MS Hood College Bioscience
08/2009 – 05/2013	Calli Rooney; MS Biotechnology, MBA

Undergraduate students:

As Principal Supervisor

Summer 2014	Megan Toms
06/2009 – 06/2011	Rachel Reading
09/2010 – 05/2011	Megan Hill
07/2007 - 09/2009	Lauren Neighbors, Mount Saint Mary's University Honors
05/2006 - 10/2007	Calli Rooney, Mount Saint Mary's University

Oak Ridge Institute for Science and Education (ORISE), mentor, laboratory leader and supervisor for part-time undergraduate students and full time post-doctoral fellows, 2008-present

10/2009 – 04/2012	Sabrina Stronsky
02/2009 - 07/2010	Blake Rust
05/2007/5 – 06/2009	Andrea Stossel MS
09/2007 – 06/2008	Lauren Neighbors
12/2008 – 10/2011	Benjamin Rush
09/2009 – 09/2013	Maryah Freeman
08/2007 – 09/2013	Priscilla Williams
01/2021 - 06/2021	Megan Toms

Hood College Mentor for undergraduate and graduate students working at
USAMRIID while enrolled at Hood College 2008 - 2013

Frederick County High School STEM & SIP program 2007 - 2013
Role: Volunteer science teacher substitute and mentor for high school students

involved in senior work study program

- c. Chair/Member of Ph.D. Supervisory Committee for: N/A
- d. Chair/Member of Masters Thesis Supervisory Committee for: N/A
- e. External Reviewer of Ph.D. dissertation of: N/A
- f. External Reviewer of Master's Thesis for: N/A

II. Teaching and Mentoring Responsibilities at Hood College:

a. Teaching:

Course: BIOL-232; Microbiology for Nurses Lecture 2020 - 2023
Academic Semester: Fall
Lecture Hours Per Semester: 3

Course: BIOL-23L; Microbiology Laboratory 2021 - 2023
Academic Semester: Fall
Lecture Hours Per Semester: 1

Course: ENSP 101; Environmental Science and Policy 2021 - 2023
Academic Semester: Fall
Lecture Hours Per Semester: 3

Course: ENSP 110; Environmental Science II 2021 - 2023
Academic Semester: Spring
Lecture Hours Per Semester: 3

Course: BMS 527; Pathogenic Microbiology, Lecture and Laboratory Course
Hood College Biomedical Sciences Master Program
Academic Semester: Spring Lecture Hours Per Semester: 4 2020-2024

b. Mentoring:

Residents/Post-doctoral fellows: N/A

Ph.D Students: N/A

Master's students: N/A

Undergraduate students:

Oak Ridge Institute for Science and Education (ORISE), mentor, laboratory leader and supervisor for part-time undergraduate students and full time post-doctoral fellows, 2008-present

MO/2021 – MO/2023 Caleb Taylor, M.S. Biomedical Science.
MO/2021 – MO/2024 Canon Hansen M.S. Hood Biomedical Science
MO/2022 – MO/2023 Josie Blair M.S. Hood Biomedical Science

- c. Chair/Member of Ph.D. Supervisory Committee for: N/A
- d. Chair/Member of Masters Thesis Supervisory Committee for: N/A
- e. External Reviewer of Ph.D. dissertation of: N/A
- f. External Reviewer of Master's Thesis for: N/A

III. Teaching and Mentoring Responsibilities at Hood College & Oyanalytika:

- a. Teaching: N/A
- b. Mentoring:

Residents/Post-doctoral fellows:

As Principal Supervisor

04/2022 – 12/2023 Ami Patel Ph.D.

09/2020 - 07/2022 Nashied Peton Ph.D.

Ph.D Students:

01/2020- Present Cyrille Mbanwi, Cameroon Department of Microbiology, University of Yaounde

02/2021 – 06/2023 Megan Toms, DVM, MPH, MLS (ASCP)CM

Master's students:

Undergraduate students:

MO/2023 - Present Benjamin Cowan

Biotechnology and Science Financial Analyst Summer Fellowship and Mentor Program Life Sciences Division Summer 2023 – 6 mentored undergraduates

- c. Chair/Member of Ph.D. Supervisory Committee for: N/A
- d. Chair/Member of Masters Thesis Supervisory Committee for: N/A
- e. External Reviewer of Ph.D. dissertation of: N/A
- f. External Reviewer of Master's Thesis for: N/A

IV. Teaching and Mentoring Responsibilities at Kansas City University:

- a. Teaching:

Course: BIOS 518; Microbiology

2019 - 2024

Co-course Director, Biomedical Sciences Master Program

Academic Semester: Spring

Lecture Hours Per Semester: 3

Course: BIOS 514; Molecular Biology & Cell Biology

2022 - 2023

Guest Lecturer, Biomedical Sciences Master Program

Academic Semester: Fall
Lecture Hours Per Semester: 3

b. Mentoring:

Residents/post-doctoral fellows: N/A

Ph. D Students: N/A

Master's students: N/A

Undergraduate students: N/A

c. Chair/Member of Ph.D. Supervisory Committee for: N/A

d. Chair/Member of Master's Thesis Supervisory Committee for: N/A

e. External Reviewer of Ph.D. dissertation of: N/A

f. External Reviewer of Master's Thesis for: N/A

V. Teaching and Mentoring Responsibilities at UTMB:

a. Teaching:

UTMB and FDA, Achieving Data Quality, and Integrity in Maximum Containment
Laboratories Course 2015 - present

b. Mentoring:

Residents/post-doctoral fellows: N/A

Ph.D Students: N/A

Master's students: N/A

Undergraduate students: N/A

c. Chair/Member of Ph.D. Supervisory Committee for: N/A

d. Chair/Member of Master's Thesis Supervisory Committee for: N/A

e. External Reviewer of Ph.D. dissertation of: N/A

f. External Reviewer of Master's Thesis for: N/A

VI. Teaching and Mentoring Responsibilities at Boston University:

a. Teaching:

Boston University Maximum Containment Training 2011 - 2024

Provided didactic and simulation training for >200 staff, guest and visiting scientists.

b. Mentoring:

Residents/post-doctoral fellows: N/A

Ph.D Students: N/A

Master's students: N/A

Undergraduate students: N/A

c. Chair/Member of Ph.D. Supervisory Committee for: N/A

d. Chair/Member of Master's Thesis Supervisory Committee for: N/A

e. External Reviewer of Ph.D. dissertation of: N/A

f. External Reviewer of Master's Thesis for: N/A

MEMBERSHIP IN SCIENTIFIC SOCIETIES/PROFESSIONAL ORGANIZATIONS:

(* denotes elected membership)

2012 Translational Biomedicine, Virology; International Scholarly Research Network
 2010 International Union of Immunological Societies (IUIS)
 2010 American Association of Pharmaceutical Scientists
 2010 National Air and Space Associate Member
 2010 Experimental Aircraft Association (EAA), Lifetime Member
 2009 American Society for Microbiology
 2009 Sigma Xi, nominated Full member*
 2008 American Chemical Society (ACS) nominated Full member*
 2008 American Association for the Advancement of Science (AAAS)
 2008 International Complement Society
 2008 PADI Diving Society, Open Water Diver
 2007 International Society for Antiviral Research (ICAR)
 2007 Professional American Association of Immunologist (AAI), Full member & Personal
 2007 American Association of Immunologist*
 2007 American Society for Virology, Full Member*
 2006 Federation of American Societies for Experimental Biology (FASEB)
 2005 Aircraft Owners and Pilots Association (AOPA), member

HONORS:

Biomedical Master's Program Faculty of the Year, Nominated by Students	2022
Department of Defense, Defense Intelligence Agency (DIA) Commander Award,	
Office of the Surgeon General, COVID Response Team Award	2021
MRIGlobal Director's Award for the development of synthetic biology and diagnostic programs.	2020
Director's Award for the development of synthetic biology and diagnostic programs	2020
MRIGlobal Spigarelli Award for exceptional commitment to Science & Engineering Education	

2019	
Samaritan's Purse Award for efforts directed at the West Africa Ebola Outbreak	2018
NIH Director's Award for Outstanding Accomplishment: NIH Ebola Patient Care Response team	2015
Honorable Order of Kentucky Colonels: Governor of Kentucky	2014
Commander's Award for Civilian Service; support of Virology Division & USARMIID	2013
Achievement Medal for Civilian Service; Emergency Response	2010
Achievement Medal for Civilian Service; BSL4 Laboratory Renovation Team	2005
National Academies Fellowship Award	2000 – 2004
<i>Alph Eta</i> Society	1993

ADDITIONAL INFORMATION:

Editorial Boards:

Over 53 published papers reviewed as a primary or guest editor reviewer of multiple journals since 2010.

Journal Reviewer for:

Served as reviewer for multiple journals including but not limited to Health Security, Vaccine, Journal of Virology, Journal of General Virology, Lancet, Nature, Nature Communications, Nature Microbiology, Nature Medicine, New England Journal of Medicine, PLoS NTD, PLoS ONE, PLoS Pathogens, Vaccine, Virology, Scientific Reports, Science, Science Reports, Science Translational Medicine, Viruses.

Grant Reviewer for:

Ad hoc reviewer on special NIH/NIAID grants, USDA, DoD and International (EU and Israel Foundation) proposals from 2010-present.

Small Business and Technology Transfer (SBIR/STTR) Study Section member

United States Department of Agriculture National Institute of Food and Agriculture (NIFAA) A1181 panel. 2022 – 2024

Military Infectious Diseases Research Program (MIDRP) Steering Committee for Lethal Viruses Research Program (Program Area T), reviewer 2008 - 2023

Program Grant (PO1) Biodefense Special Study Section 2020

NIH/NIAID Center for Scientific Review Special Emphasis Panel/SBIR 2008 - 2012

HIV molecular virology, cell biology, and drug development 2005 – 2011

FLC Excellence in Technology Transfer Award Evaluator Panel 2009

Chemical & Biological Defense Directorate Defense Threat Reduction Agency Extramural Phase I & Phase II reviewer 2007

Professional Skills (e.g. professional development endeavors)

Outbreak response: Experienced in Mobile laboratory supervisor/manager, operator and trainer. Fast and travel-friendly deployment of mobile laboratories at viral outbreaks locations, namely for Ebola and COVID-19 diagnostic.

Biosafety: High-level expertise on high-consequence pathogens and their handling in BSL3 and BSL4 conditions.

Contract Officer Representative – government role assisting contract officer on technical oversight of contracts up to \$2.0 million.

Department of Defense (DoD) Defense Acquisition University (DAU) Acquisition Training, Level III Scientific Programmatic Oversight

USAMRIID Study Director – non-clinical preclinical training 2013

Human Research Protection Training NIH Office of Human Research Protection 2013
IACUC Working with the IACUC American Association for the Laboratory Animal Science 2010

AAALAC Review Team Training 2015

Collaborative Institutional Training Initiative CITI Biomedical Responsible Conduct of Research 3 May 2024

Collaborative Institutional Training Initiative CITI Health Information Privacy and Security (HIPS) for Clinical Investigators 3 May 2024

Collaborative Institutional Training Initiative CITI Biomedical Research 3 May 2024

Collaborative Institutional Training Initiative CITI Revised Common Rule 26 May 2024

Collaborative Institutional Training Initiative CITI Data Safety Monitoring Committee: A Guide for New Leaders and Members. 1 March 2023

Collaborative Institutional Training Initiative CITI Data Safety Monitoring New Data and Safety Monitoring Module. 6 March 2023

Patents Awarded:

1. Polyak, Stephen J., Johansen, Lisa, White, Judith M., Xu, Shuang, Schiffer Joshua, T., Olinger, G., Finch Courtney L., Dyall, J. International Patent WO US 2022/173841A1. Methods of Modeling In Vivo Efficacy of Drug Combinations for Treatment of Viral Infections. Assignee: University of Virginia Patent Foundation. The US Department of Health and Human Services, and Fred Hutchinson Cancer Research Center. Feb 2, 2023
2. Polyak, Stephen J., Johansen, Lisa, White, Judith M., Xu, Shuang, Schiffer Joshua, T., Olinger, G., Finch Courtney L., Dyall, J. International Patent US20240127967A1. Methods of Modeling In Vivo Efficacy of Drug

Combinations for Treatment of Viral Infections. Assignee: University of Virginia Patent Foundation. The US Department of Health and Human Services, and Fred Hutchinson Cancer Research Center. April 18, 2024

3. IMMUNOGENIC COMPOSITIONS AND VACCINES FOR EBOLA.
Inventors: Kate, Mary, Gene Olinger Jr., Mike Bailey, and Michael Adam
U.S. Patent No. 7,736,656. Submitted: 15 June 2010.
4. EBOLA PEPTIDES AND IMMUNOGENIC COMPOSITIONS CONTAINING SAME
Hart, Mary Katherine, Julie Ann Wilson, Gene Olinger, Jr., Mike Bailey, and Michael Adam, U.S. Patent No. 7,267,823. Submitted: 11 September 2007.
5. Johansen, Lisa M., Joseph Lehar, Benjamin G. Hoffstrom, Gene G. Olinger, and Andrea R. Stossel, U.S. Patent US8475804B2 Compositions and methods for treatment of filovirus-mediated diseases, February 22, 2010.

Patent Applications or Provisional Patents:

1. Chang, Eddie L., Lisa Hensley, Dzung C. Thach, Andy Knight, and G. G. Olinger, U.S. Patent Application 20110027388 Cobalt Hexammine as a Potential Therapeutic Against HIV and/or Ebola Virus Gene, July 30, 2010.
2. Michelow, Ian, Emmett V. Schmidt, Kazue Takahashi, and Gene G. Olinger, U.S. Patent Application 20100331240 Methods for prevention and treatment of infections with supraphysiological doses of mannan-binding lectin (mb1) and ficolin-mbl fusion protein: July 16, 2010.

PUBLICATIONS:

A. ARTICLES IN PEER-REVIEWED JOURNALS (108):

[Scopus Author ID: 7006751100](#)
[SciProfiles: 1519484](#)
<https://orcid.org/0000-0001-7338-0292>

Microbiology D-index 54 Citations 9,967 Publications 108, World Ranking 3459 National Ranking 1392

1. Climate change and infectious disease: A prologue on multidisciplinary cooperation and predictive analytics. Yeh KB, Parekh FK, Mombo I, Leimer J, Hewson R, Olinger G, Fair JM, Sun Y, Hay J. Front Public Health. 2023 Jan 20;11:1018293. doi: 10.3389/fpubh.2023.1018293. eCollection 2023. PMID: 36741948
2. Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses. White JM, Schiffer JT, Bender Ignacio RA, Xu S, Kainov D, Ianevski A, Aittokallio T, Frieman M, Olinger GG, Polyak SJ. mBio. 2021 Dec 21;12(6):e0334721. Doi: 10.1128/mbio.03347-21. Epub 2021 Dec 21. PMID: 34933447; PMCID: PMC8689562.
3. SARS-CoV-2 Supply Shortages and Tuberculosis Diagnostics: Current Issues Requiring Immediate Solutions. Armstrong DT, Tacheney EA, Olinger G, Howard R, Lemmon MM,

Dasgupta D, Eisemann E, Parrish N. J Clin Microbiol. 2021 Nov 18;59(12):e0077821. doi: 10.1128/JCM.00778-21. Epub 2021 Sep 29. PMID: 34586893; PMCID: PMC8601221.

4. First Movers in Molecular Detection: Case Comparison on Harnessing Research and Development, Industry, and Entrepreneurship. Yeh KB, Scullion M, Michelotti JM, Olinger G. Front Med (Lausanne). 2021 Mar 25;8:639440. doi: 10.3389/fmed.2021.639440. PMID: 33842501; PMCID: PMC8026858.
5. Significance of High-Containment Biological Laboratories Performing Work During the COVID-19 Pandemic: Biosafety Level-3 and -4 Labs. Yeh KB, Tabynov K, Parekh FK, Mombo I, Parker K, Tabynov K, Bradrick SS, Tseng AS, Yang JR, Gardiner L, Olinger G, Setser B. Front Bioeng Biotechnol. 2021 Aug 13;9:720315. doi: 10.3389/fbioe.2021.720315. PMID: 34485259; PMCID: PMC8414973.
6. Inhibition of Arenaviruses by Combinations of Orally Available Approved Drugs. Antimicrob Agents Chemother. Herring, S., J.M. Oda, J. Wagoner, D. Kirchmeier, A. O'Connor, E.A. Nelson, Q. Huang, Y. Liang, L.E. DeWald, L.M. Johansen, P.J. Glass, G.G. Olinger, A. Ianevski, T. Aittokallio, M.F. Paine, S.L. Fink, J.M. White, S.J. Polyak. 2021 Mar 18;65(4):e01146-20. doi: 10.1128/AAC.01146-20. Print 2021 Mar 18. PMID: 33468464
7. COVID-19 vaccines: Global challenges and prospects forum recommendations. Boudjelal, M., F. Almajed, A.M. Salman, N.K. Alharbi, M. Colangelo, J.M. Michelotti, G. Olinger, M. Baker, A.V.S. Vill, A. Alaskar. Int J Infect Dis. 2021 Feb 27;105:448-451. doi: 10.1016/j.ijid.2021.02.093. Online ahead of print. PMID: 33652065
8. Formulation, Stability, Pharmacokinetic, and Modeling Studies for Tests of Synergistic Combinations of Orally Available Approved Drugs against Ebola Virus In Vivo. Finch, C.L., J. Dyall, S. Xu, E.A. Nelson, E. Postnikova, J.Y. Liang, H. Zhou, L.E. DeWald, C.J. Thomas, A. Wang, X. Xu, E. Hughes, P.J. Morris, J.C. Mirsalis, L.H. Nguyen, M.P. Arolfo, B. Koci, M.R. Holbrook, L.E. Hensley, P.B. Jahrling, C. Schmaljohn, L.M. Johansen, G.G. Olinger, J.T. Schiffer, J.M. White. Microorganisms. 2021 Mar 10;9(3):566. doi: 10.3390/microorganisms9030566. PMID: 33801811
9. Lacy-Hulbert MHC class II transactivator CIITA induces cell resistance to Ebola virus and SARS-like coronaviruses. Bruchez, A., K. Sha, J. Johnson, L. Chen, C. Stefani, H. McConnell, L. Gaucherand, R. Prins, K.A. Matreyek, A.J. Hume, E. Mühlberger, E.V. Schmidt, G.G. Olinger, L.M. Stuart, A. [published online ahead of print, 2020 Aug 27]. Science. 2020;eabb3753. doi:10.1126/science.abb3753
10. Project IDentif.AI: Harnessing Artificial Intelligence to Rapidly Optimize Combination Therapy Development for Infectious Disease Intervention. Abdulla A, Wang B, Qian F, Kee T, Blasiak A, Hun Ong Y, Hooi L, Parekh F, Soriano R, Olinger G, Keppo J, Hardesty CJ, Chow EK, Ho D, Ding. Adv Ther (Weinh) 2020 Apr 16.
11. Infectious Disease Risks and Vulnerabilities in the Aftermath of an Environmental Disaster in Minas Gerais, Brazil. Parekh, F.K., K.B. Yeh, G. Olinger, F.A. Ribeiro. Vector Borne Zoonotic Dis. 2020 May;20(5):387-389.

12. Enhancing laboratory capacity during Ebola virus disease (EVD) heightened surveillance in Liberia: lessons learned and recommendations. Katawera, V, H. Kohar, N. Mahmoud, P. Raftery, C. Wasunna, B. Humrighouse, P. Hardy, J. Saindon, R. Schoepp, M. Makvandi, L. Hensley, O. Condell, K. Durski, S. Singaravelu, L. Gahimbare, G. Olinger F.Kateh, D. Naidoo, P. Nsubuga, P. Formenty, T. Nyenswah, S.O. Coulibaly, J.C. Okeibunor, A. Talisuna A.A. Yahaya, S. Rajatonirina, D.Williams, B. Dahn, A. Gasasira. Fall IS.Pan Afr Med J. 2019 May 29;33(Suppl 2):8.
13. Inhibition of Ebola Virus by a Molecularly Engineered Banana Lectin. Covés-Datson, E.M., J. Dyall, L.E. DeWald, S.R. King, D. Dube, M. Legendre, E. Nelson, K.C. Drews, R. Gross, D.M. Gerhardt, L. Torzewski, E. Postnikova, J.Y. Liang, B. Ban, J. Shetty, L.E. Hensley, P.B. Jahrling, G.G. Olinger, Jr, J.M. White, D.M. Markovitz. .PLoS Negl Trop Dis. 2019 Jul 29;13(7):e0007595.
14. Ebola Virus Isolation Using Huh-7 Cells has Methodological Advantages and Similar Sensitivity to Isolation Using Other Cell Types and Suckling BALB/c Laboratory Mice. Logue, J., W. Vargas Licona, T.K. Cooper, B. Reeder, R. Byrum, J. Qin, M.N. Deiuliis, Y. Cong, A. Bonilla, J. Sword, W. Weaver, G. Kocher, G.G. Olinger, P.B. Jahrling, L.E. Hensley, R.S. Bennett. Viruses. 2019 Feb 16;11(2):161.
15. The Convergence of High-Consequence Livestock and Human Pathogen Research and Development: A Paradox of Zoonotic Disease. Michelotti, J.M., K.B. Yeh, T.R. Beckham, M.M Colby, D. Dasgupta, K.A. Zuelke, G.G. Olinger. Trop Med Infect Dis. 2018 May 30;3(2):55.
16. Pan-Filovirus Serum Neutralizing Antibodies in a Subset of Congolese Ebolavirus Infection Survivors. Bramble, M.S., N. Hoff, P. Gilchuk, P. Mukadi, K. Lu, R.H. Doshi, I. Steffen, B.P. Nicholson, A. Lipson, N. Vashist, C. Sinai, D. Spencer, G. Olinger, E.O. Wemakoy, B.K. Illunga, J. Pettitt, J. Logue, J. Marchand, J. Varughese, R.S. Bennett, P. Jahrling, G. Cavet, T. Serafini, S.E. Ollmann, E. Vilain, J.J. Muyembe-Tamfum, L.E. Hensely, G. Simmons, J.E. Crowe, Jr, A.W. Rimoin. J Infect Dis. 2018 Nov 5;218(12):1929-1936.
17. In Vitro and In Vivo Activity of Amiodarone Against Ebola Virus. Dyall,J., J.C. Johnson, B.J. Hart, E. Postnikova, Y. Cong, H. Zhou, D.M. Gerhardt, J. Michelotti, A.N. Honko, S. Kern, L.E. DeWald, K.G. O'Loughlin, C. E. Green, J.C. Mirsalis, R.S. Bennett, G.G. Olinger, Jr, P.B. Jahrling, L.E. Hensley. J Infect Dis. 2018 Nov 22;218(suppl_5):S592-S596.
18. Fully Human Immunoglobulin G From Transchromosomal Bovines Treats Nonhuman Primates Infected With Ebola Virus Makona Isolate. Version 2. Luke, T, R.S. Bennett, D.M. Gerhardt, T. Burdette, E. Postnikova, S. Mazur, A.N. Honko, N. Oberlander, R. Byrum, D. Ragland, M. St Claire, K.B. Janosko, G. Smith, G. Glenn, J. Hooper, J. Dye, S. Pal, K.A. Bishop-Lilly, T. Hamilton, K. Frey, L. Bollinger, J. Wada, H. Wu, J.A. Jiao, G.G. Olinger, B. Gunn, G. Alter, S. Khurana, L.E. Hensley, E. Sullivan, P.B. Jahrling. J Infect Dis. 2018 Nov 22;218(suppl_5):S636-S648.
19. The Calcium Channel Blocker Bepridil Demonstrates Efficacy in the Murine Model of Marburg Virus Disease. DeWald, L.E., J. Dyall, J.M. Sword, L. Torzewski, H. Zhou, E. Postnikova, E. Kollins, I. Alexander, R. Gross, Y. Cong, D.M. Gerhardt, R.F Johnson,

G.G. Olinger, Jr, M.R. Holbrook, L.E. Hensley, J.B. Jahrling. J Infect Dis. 2018 Nov 22;218(suppl_5):S588-S591.

20. Identification of Combinations of Approved Drugs With Synergistic Activity Against Ebola Virus in Cell Cultures. Dyall, J., E.A. Nelson, L.E. DeWald, R. Guha, B.J. Hart, H. Zhou, E. Postnikova, J. Logue, W.M. Vargas, R. Gross, J. Michelotti, N. Deiuliis, R.S. Bennett, I. Crozier, M.R. Holbrook, P.J. Morris, C. Klumpp-Thomas, C. McKnight, T. Mierzwa, P. Shinn, P.J. Glass, L.M. Johansen, P.B. Jahrling, L.E. Hensley, G.G. Olinger, Jr, C. Thomas, J.M. White. J Infect Dis. 2018 Nov 22;218(suppl_5):S672-S678.
21. Avian Influenza Is a Catalyst for Economic and Political Destabilization in Iran. Olinger, G.G., K.B. Yeh. Health Secur. 2018 Mar/Apr;16(2):143.
22. Testing therapeutics in cell-based assays: Factors that influence the apparent potency of drugs. Postnikova, .E., Y. Cong, L.E. DeWald, J. Dyall, S.Yu, B.J. Hart, H. Zhou, R.Gross, J. Logue, Y.Cai, N. Deiuliis, J. Michelotti, A.N. Honko, R.S. Bennett, M.R. Holbrook, G.G Olinger, L.E. Hensley, P.B Jahrling. PLoS One. 2018 Mar 22;13(3):e0194880.
23. Use of the Filovirus Animal Non-Clinical Group (FANG) Ebola virus immuno-assay requires fewer study participants to power a study than the Alpha Diagnostic International assay. Logue, J., K. Tuznik, D. Follmann, G. Grandits, J. Marchand, C. Reilly, Y.D.S. Sarro, J. Pettitt, E.J. Stavale, M. Fallah, G.G. Olinger, F.K. Bolay, L.E. Hensley. Virol Methods. 2018 May;255:84-90. doi: 10.1016/j.jviromet.2018.02.018. Epub 2018 Feb 23.
24. Ebola Virus Neutralizing Antibodies Detectable in Survivors of the Yambuku, Zaire Outbreak 40 Years after Infection. Rimoin, A.W., K. Lu, M.S. Bramble, I. Steffen, R.H. Doshi, N.A. Hoff, P. Mukadi, B.P. Nicholson, V.H. Alfonso, G. Olinger, C. Sinai, L.K. Yamamoto, C.M. Ramirez, E. Okitolonda Wemakoy, B. Kebela Illunga, J. Pettitt, J. Logue, R.S. Bennett, P. Jahrling, D.L. Heymann, P. Piot, J.J. Muyembe-Tamfum, L.E. Hensley, G. Simmons. J Infect Dis. 2018 Jan 4;217(2):223-231.
25. Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies. Dyall, J, R. Gross, J. Kindrachuk, R.F. Johnson, G.G.Olinger, Jr., L.E. Hensley, M.B. Frieman, P.B. Jahrling. Drugs. 2017 Dec;77(18):1935-1966. doi: 10.1007/s40265-017-0830-1. Review.
26. Nonhuman Primate Models of Ebola Virus Disease. Bennett, R.S., L.M. Huzella, P.B. Jahrling, L. Bollinger, G.G.Olinger, Jr, L.E.Hensley. Curr Top Microbiol Immunol. 2017;411:171-193
27. Vesicular stomatitis virus pseudotyped with Ebola virus glycoprotein serves as a protective, non-infectious vaccine against Ebola virus challenge in mice. Lennemann, N.J., A.S. Herbert, R. Brouillette, B. Rhein, R.A. Bakken, K.J. Perschbacher, A.L. Cooney, C.L. Miller-Hunt, P. Ten Eyck, J. Biggins, G. Olinger, J.M. Dye, W. Maury. J Virol. 2017 Jun 14. pii: JVI.00479-17.
28. High dose sertraline monotherapy fails to protect rhesus macaques from lethal challenge with Ebola virus Makona. Honko, A.N., J.C. Johnson, J.S. Marchand, L. Huzella, R.D. Adams, N. Oberlander, L.M. Torzewski, R.S. Bennett, L.E. Hensley, P.B. Jahrling, G.G. Olinger. Sci Rep. 2017 Jul 19;7(1):5886. doi: 10.1038/s41598-017-06179-y.

29. Therapeutics Against Filovirus Infection. Connor, J., G. Kobinger, G. Olinger. *Curr Top Microbiol Immunol.* 2017;411:263-290.
30. The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection. Nelson, E. A., J. Dyall, T. Hoenen, A.B. Barnes, H. Zhou, J.Y. Liang, J. Michelotti J, W. H. Dewey, L.E. DeWald, R. S. Bennett, P.J. Morris, R. Guha, C. Klumpp-Thomas, C. McKnight, Y.C. Chen, X. Xu A. Wang, E. Hughes, S. Martin, C. Thomas, P.B. Jahrling, L.E. Hensley, G.G. Olinger, Jr, J.M. White. *PLoS Negl Trop Dis.* 2017 Apr 12;11(4):e0005540.
31. Interferon- β and Interferon- γ Are Weak Inhibitors of Ebola Virus in Cell-Based Assays. Dyall, J., B. J. Hart, E. Postnikova, Y. Cong, H. Zhou, D.M. Gerhardt, D. Freeburger, J. Michelotti, A.N. Honko, L.E. DeWald, R.S. Bennett, G. G. Olinger, P. B. Jahrling, L. E. Hensley. *J Infect Dis.* 2017 May 1;215(9):1416-1420.
32. The lipid moiety of brincidofovir is required for in vitro antiviral activity against Ebola virus. McMullan, L.K., M. Flint, J. Dyall, C. Albariño, G. G. Olinger, S. Foster, P. Sethna, L. E. Hensley, S. T. Nichol, E. R. Lanier, C. F. Spiropoulou. *Antiviral Res.* 2016 Jan;125:71-8.
33. Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo. Luke, T., H. Wu, J. Zhao, R. Channappanavar, C. M. Coleman, J.A. Jiao, H. Matsushita, Y. Liu, E. N. Postnikova, B. L. Ork, G. Glenn, D. Flyer, G. Defang, K. Raviprakash, T. Kochel, J. Wang, W. Nie, G. Smith, L.E Hensley, G. G. Olinger, J. H. Kuhn, M. R. Holbrook, R. F. Johnson, S. Perlman, E. Sullivan, M. B. Frieman. *Sci Transl Med.* 2016 Feb 17;8(326):326ra21.
34. Evaluation of the Activity of Lamivudine and Zidovudine against Ebola Virus. Cong, Y., J. Dyall, B. J. Hart, L. E. DeWald, J. C. Johnson, E. Postnikova, H. Zhou, R. Gross, O. Rojas, I. Alexander, N. Josleyn, T. Zhang, J. Michelotti, K. Janosko, P.J. Glass, M. Flint, L. K. McMullan, C. F. Spiropoulou, T. Mierzwa, R. Guha, P. Shinn, S. Michael, C. Klumpp-Thomas, C. McKnight, C. Thomas, A. E. Eakin, K. G. O'Loughlin, C. E. Green, P. Catz, J. C. Mirsalis, A. N. Honko, G. G. Olinger, Jr, R. S. Bennett, M. R. Holbrook, L. E. Hensley, P.B. Jahrling. *PLoS One.* 2016 Nov 30;11(11):e0166318.
35. 3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012. Johnson, R.F., U. Bagci, L. Keith, X. Tang, D.J. Mollura, L. Zeitlin, J. Qin, L. Huzella, C.J. Bartos, N. Bohorova, O. Bohorov, C. Goodman, D.H. Kim, M.H. Paulty, J. Velasco, K.J. Whaley, J.C. Johnson, J. Pettitt J, B. L. Ork, J. Solomon, N. Oberlander, Q. Zhu, J. Sun, M.R. Holbrook, G.G. Olinger, R.S. Baric, L.E. Hensley, P.B. Jahrling, W.A. Marasco. *Virology.* 2016 Jan 29;490:49-58.
36. Antibody therapeutics for Ebola virus disease. Zeitlin, L., K.J. Whaley, G.G. Olinger, M. Jacobs, R. Gopal, X. Qiu, G.P. Kobinger. *Curr Opin Virol.* 2016 Jan 27;17:45-49.
37. The lipid moiety of brincidofovir is required for in vitro antiviral activity against Ebola virus. McMullan, L.K., M. Flint, J. Dyall, C. Albariño, G. Olinger, S. Foster, P. Sethna, L.E. Hensley, S.T. Nichol, E.R. Lanier, C.F. Spiropoulou. *Antiviral Res.* 2015 Oct 22. pii: S0166-3542(15)30011-5.

38. Emergence of Ebola Virus Escape Variants in Infected Nonhuman Primates Treated with the MB-003 Antibody Cocktail. Kugelman, J.R., J. Kugelman-Tonos, J.T. Ladner, J. Pettit, C.M. Keeton, E.R. Nagle, K.Y. Garcia, J.W. Froude, A.I. Kuehne, J.H. Kuhn, S. Bavari, L. Zeitlin, J.M. Dye, G.G. Olinger, M. Sanchez-Lockhart, G.F. Palacios. *Cell Rep.* 2015 Sep 29;12(12):2111-20.
39. Viral Hemorrhagic Fever Diagnostics. Racsa, L.D., C.S. Kraft, G.G. Olinger, L.E. Hensley. *Clin Infect Dis.* 2015 Sep 9.
40. Fighting Ebola with novel spore decontamination technologies for the military. Doona, C.J., F.E. Feeherry, K. Kustin, G.G. Olinger, P. Setlow, A.J. Malkin, T. Leighton. *Front Microbiol.* 2015 Aug 12;6:663
41. Evaluation of candidate vaccine approaches for MERS-CoV. Wang L, W. Shi, MG. Joyce, K. Modjarrad, Y. Zhang, K. Leung, CR. Lees, T. Zhou, HM. Yassine, M. Kanekiyo, ZY. Yang, X. Chen, MM. Becker, M. Freeman, L. Vogel, JC. Johnson, G. Olinger, JP. Todd, U. Bagci, J. Solomon, DJ. Mollura, L. Hensley, P. Jahrling, MR. Denison, SS. Rao, K. Subbarao, PD. Kwong, JR. Mascola, WP. Kong, BS. Graham. *Nat Commun.* 2015 Jul 28;6:7712.
42. Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists. Cheng H, CM. Lear-Rooney, L. Johansen, E. Varhegyi, ZW. Chen, GG. Olinger, L. Rong. *J Virol.* 2015 Oct 1;89(19):9932-8.
43. Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses. Meyer M, T. Garron, NM. Lubaki, CE. Mire, KA. Fenton, C. Klages, GG. Olinger, TW. Geisbert, PL. Collins, A. Bukreyev. *J Clin Invest.* 2015 Aug 3;125(8):3241-55.
44. Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus Gps. Fusco ML, T. Hashiguchi, R. Cassan, JE. Biggins, CD. Murin, KL. Warfield, S. Li, FW. Holtsberg, S. Shulenin, H. Vu, GG. Olinger, H. Kim do, KJ. Whaley, L. Zeitlin, AB. Ward, C. Nykiforuk, MJ. Aman, J. Berry, EO. Saphire. *PLoS Pathog.* 2015 Jun 26;11(6)
45. A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity. Johansen LM, LE. DeWald, CJ. Shoemaker, BG. Hoffstrom, CM. Lear-Rooney, A. Stossel, E. Nelson, SE. Delos, JA. Simmons, JM. Grenier, LT. Pierce, H. Pajouhesh, J. Lehár, LE. Hensley, PJ. Glass, JM. White, GG. Olinger. *Sci Transl Med.* 2015 Jun 3; 7(290):290ra89.
46. Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study. Clark DV, H. Kibuuka, M. Millard, S. Wakabi, L. Lukwago, A. Taylor, MA. Eller, LA. Eller, NL. Michael, AN. Honko, GG. Olinger Jr, RJ. Schoepp, MJ. Hepburn, LE. Hensley, ML. Robb. *Lancet Infect Dis.* 2015 Apr 21. pii: S1473-3099(15)70152-0. doi: 10.1016/S1473-3099(15)70152-0
47. Role of EXT1 and Glycosaminoglycans in the Early Stage of Filovirus Entry. O'Hearn A, M. Wang, H. Cheng, CM. Lear-Rooney, K. Koning, E. Rumschlag-Booms, E. Varhegyi, G. Olinger, L. Rong. *J Virol.* 2015 May 15;89(10):5441-9. doi: 10.1128/JVI.03689-14. Epub 2015 Mar 4.

48. Lack of effect of Lamivudine on ebola virus replication. Hensley LE, J. Dyall, GG. Olinger Jr, PB. Jahrling. *Emerg Infect Dis.* 2015 Mar; 21(3):550-2. doi: 10.3201/eid2103.141862.
49. The Antiviral Potential of ERK/MAPK and PI3K/AKT/mTOR Signaling Modulation for MERS-CoV Infection as Identified by Temporal Kinome Analysis. Kindrachuk J, B. Ork, BJ. Hart, S. Mazur, MR. Holbrook, MB. Frieman, D. Traynor, RF. Johnson, J. Dyall, JH. Kuhn, GG. Olinger, LE. Hensley, PB. Jahrling. *Antimicrob Agents Chemother.* 2014 Dec 8. pii: AAC.03659-14.
50. Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Murin CD, ML. Fusco, ZA. Bornholdt, X. Qiu, GG. Olinger, L. Zeitlin, GP. Kobinger, AB. Ward, EO. Saphire. *Proc Natl Acad Sci U S A.* 2014 Dec 2;111(48):17182-7. doi: 10.1073/pnas.1414164111.
51. The cyanobacterial lectin scytovirin displays potent in vitro and in vivo activity against Zaire Ebola virus. Garrison AR, BG. Giomarelli, CM. Lear-Rooney, CJ. Saucedo, S. Yellayi, LR. Krumpe, M. Rose, J. Paragas, M. Bray, GG. Olinger Jr, JB. McMahon, J. Huggins, BR. O'Keefe. *Antiviral Res.* 2014 Dec;112:1-7. doi: 10.1016/j.antiviral.2014.09.012.
52. Filovirus RefSeq entries: evaluation and selection of filovirus type variants, type sequences, and names. Kuhn JH, KG. Andersen, Y. Bào, S. Bavari, S. Becker, et al. GG. Olinger, ST. Nichol. *Viruses.* 2014 Sep 26;6(9):3663-82. doi: 10.3390/v6093663.
53. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Qiu X, G. Wong, J. Audet, A. Bello, L. Fernando, JB. Alimonti, H. Fausther-Bovendo, H. Wei, J. Aviles, E. Hiatt, A. Johnson, J. Morton, K. Swope, O. Bohorov, N. Bohorova, C. Goodman, D. Kim, MH. Pauly, J. Velasco, J. Pettitt, GG. Olinger, K. Whaley, B. Xu, JE. Strong, L. Zeitlin, GP. Kobinger. *Nature* 2014 Aug 29.
54. Vaccinating captive chimpanzees to save wild chimpanzees. Warfield KL, JE. Goetzmann, JE. Biggins, MB. Kasda, RC. Unifer, H. Vu, MJ. Aman, GG. Olinger Jr, PD. Walsh. *Proc Natl Acad Sci USA,* 2014 May 27.
55. Repurposing of clinically developed drugs for treatment of Middle East Respiratory Coronavirus Infection. Dyall J, CM. Coleman, BJ. Hart, T. Venkataraman, MR. Holbrook, J. Kindrachuk, RF. Johnson, GG. Olinger Jr, PB. Jahrling, M. Laidlaw, LM. Johansen, CM. Lear, PJ. Glass, LE. Hensley, MB. Frieman. *Antimicrob Agents Chemother.* 2014 May 19.
56. Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human cells. Johnson JC, O. Martinez, AN. Honko, LE. Hensley, GG. Olinger, CF. Basler. *Antiviral Res.* 2014 Jul;107:102-9.
57. Post-exposure therapy of filovirus infections. Wong G, X. Qiu, GG. Olinger, GP. Kobinger. *Trends Microbiol.* 2014 Apr 30.
58. Interferon- β mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. Hart BJ, J. Dyall, E. Postnikova, H. Zhou, J.

Kindrachuk, RF. Johnson, GG. Olinger Jr, MB. Frieman, MR. Holbrook, PB. Jahrling, L. Hensley. J Gen Virol. 2014 Mar;95(Pt 3):571-7. doi: 10.1099/vir.0.061911-0.

59. Correction: Multiple Cationic Amphiphiles Induce a Niemann-Pick C Phenotype and Inhibit Ebola Virus Entry and Infection. Shoemaker CJ, KL. Schornberg, SE. Delos, C. Scully, H. Pajouhesh, GG. Olinger, LM. Johansen, JM. White. PLoS One. 2013 Oct 1;8(10).
60. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Pettitt J, L. Zeitlin, H. Kim do, C. Working, JC. Johnson, O. Bohorov, B. Bratcher, E. Hiatt, SD. Hume, AK. Johnson, J. Morton, MH. Pauly, KJ. Whaley, MF. Ingram, A. Zovanyi, M. Heinrich, A. Piper, J. Zelko, GG. Olinger. Sci Transl Med. 2013 Aug 21;5(199):199ra113.
61. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Johansen LM, JM. Brannan, SE. Delos, CJ. Shoemaker, A. Stossel, C. Lear, BG. Hoffstrom, LE. Dewald, KL. Schornberg, C. Scully, J. Lehar, LE. Hensley, JM. White, GG. Olinger. Sci Transl Med. 2013 Jun 19;5(190):190ra79.
62. Comparison of the plaque assay and 50% tissue culture infectious dose assay as methods for measuring filovirus infectivity. Smither SJ, C. Lear-Rooney, J. Biggins, J. Pettitt, MS. Lever, GG. Olinger. J Virol Methods. 2013 Nov;193(2):565-71.
63. Aerosol exposure to Rift Valley fever virus causes earlier and more severe neuropathology in the murine model, which has important implications for therapeutic development. Reed C, K. Lin, C. Wilhelmsen, B. Friedrich, A. Nalca, A. Keeney, G. Donnelly, J. Shamblin, LE. Hensley, G. Olinger, DR. Smith. PLoS Negl Trop Dis. 2013 Apr 4;7(4):e2156.
64. Lectin-dependent enhancement of Ebola virus infection via soluble and transmembrane C-type lectin receptors. Brudner M, M. Karpel, C. Lear, L. Chen, LM. Yantosca, C. Scully, A. Sarraju, A. Sokolovska, MR. Zariffard, DP. Eisen, BA. Mungall, DN. Kotton, A. Omari, IC. Huang, M. Farzan, K. Takahashi, L. Stuart, GL. Stahl, AB. Ezekowitz, GT. Spear, GG. Olinger, EV. Schmidt, IC. Michelow. PLoS One. 2013;8(4):e60838.
65. Multiple cationic amphiphiles induce a Niemann-Pick C phenotype and inhibit Ebola virus entry and infection. Shoemaker CJ, KL. Schornberg, SE. Delos, C. Scully, H. Pajouhesh, GG. Olinger, LM. Johansen, JM. White. PLoS One. 2013;8(2):e56265.
66. Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus. Herbert AS, AI. Kuehne, JF. Barth, RA. Ortiz, DK. Nichols, SE. Zak, SW. Stonier, MA. Muhammad, RR. Bakken, LI. Prugar, GG. Olinger, JL. Groebner, JS. Lee, WD. Pratt, M. Custer, KI. Kamrud, JF. Smith, MK. Hart, JM. Dye. J Virol. 2013 May;87(9):4952-64.
67. Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA. Kuhn JH, Y. Bao, S. Bavari, S. Becker, S. Bradfute, K. Brauburger, J. Rodney Brister, AA. Bukreyev, Y. Cai, K. Chandran, RA. Davey, O. Dolnik, JM. Dye, S. Enterlein, JP. Gonzalez, P. Formenty, AN. Freiberg, LE. Hensley, T. Hoenen, AN. Honko, GM. Ignatyev, PB. Jahrling, KM. Johnson, HD. Klenk, G. Kobinger, MG. Lackemeyer, EM. Leroy, MS. Lever, E. Mühlberger, SV. Netesov,

- GG. Olinger, G. Palacios, JL. Patterson, JT. Paweska, L. Pitt, SR. Radoshitzky, EI. Ryabchikova, EO. Sapphire, AM. Shestopalov, SJ. Smither, NJ. Sullivan, R. Swanepoel, A. Takada, JS. Towner, G. van der Groen, VE. Volchkov, VA. Volchkova, V. Wahl-Jensen, TK. Warren, KL. Warfield, M. Weidmann, ST. Nichol. Arch Virol. 2013 Nov 5.
68. Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae. Kuhn JH, Y. Bao, S. Bavari, S. Becker, S. Bradfute, JR. Brister, AA. Bukreyev, Y. Cai, K. Chandran, RA. Davey, O. Dolnik, JM. Dye, S. Enterlein, JP. Gonzalez, P. Formenty, AN. Freiberg, LE. Hensley, AN. Honko, GM. Ignatyev, PB. Jahrling, KM. Johnson, HD. Klenk, G. Kobinger, MG. Lackemeyer, EM. Leroy, MS. Lever, LL. Lofts, E. Mühlberger, SV. Netesov, GG. Olinger, G. Palacios, JL. Patterson, JT. Paweska, L. Pitt, SR. Radoshitzky, EI. Ryabchikova, EO. Sapphire, AM. Shestopalov, SJ. Smither, NJ. Sullivan, R. Swanepoel, A. Takada, JS. Towner, G. van der Groen, VE. Volchkov, V. Wahl-Jensen, TK. Warren, KL. Warfield, M. Weidmann, ST. Nichol. Arch Virol. 2013 Jun;158(6):1425-32.
 69. Ebola virus exploits a monocyte differentiation program to promote its entry. Martinez O, JC. Johnson, A. Honko, B. Yen, RS. Shabman, LE. Hensley, GG. Olinger, CF. Basler. J Virol. 2013 Apr;87(7):3801-14.
 70. Pathology of experimental aerosol Zaire ebolavirus infection in rhesus macaques. Twenhafel NA, ME. Mattix, JC. Johnson, CG. Robinson, WD. Pratt, KA. Cashman, V. Wahl-Jensen, C. Terry, GG. Olinger, LE. Hensley, AN. Honko. Vet Pathol. 2013 May;50(3):514-29.
 71. Interferon- β therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever. Smith LM, LE. Hensley, TW. Geisbert, J. Johnson, A. Stossel, A. Honko, JY. Yen, J. Geisbert, J. Paragas, E. Fritz, G. Olinger, HA. Young, KH. Rubins, CL. Karp. J Infect Dis. 2013 Jul 15;208(2):310-8.
 72. Filovirus Animal Nonclinical Group (FANG) Assay Working Group. Standardization of the filovirus plaque assay for use in preclinical studies. Shurtleff AC, JE. Biggins, AE. Keeney, EE. Zumbrun, HA. Bloomfield, A. Kuehne, JL. Audet, KJ. Alfson, A. Griffiths, GG. Olinger, S. Bavari; Viruses. 2012 Dec 6;4(12):3511-30.
 73. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Olinger, G. G., J. Pettitt, K. Dom, C. Working, O. Bohorov, B. Bratcher, E. Hiatt, S. D. Hume, A. K. Johnson, J. Morton, M. Pauly, K. J. Whaley, C. M., Lear, J. E. Biggins, C. Scully, L. Hensley, L. Zeitlin, PNAS. October 15, 2012.
 74. Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae. Kuhn, J. H., S. Bavari, S. Becker, G. G. Olinger, et al. Arch Virol, September 23, 2012.
 75. Potential Vaccines and Post-Exposure Treatments for Filovirus Infections. Friedrich, Brian M., John C. Trefry, Julia E. Biggins, Lisa E. Hensley, Anna N. Honko, Darci R. Smith, G. G. Olinger. Review: Viruses, 4(9), 1619-1650, 2012.
 76. Assessment of High Throughput Screening (HTS) Methods for High Consequence Pathogens, Journal of Bioterrorism and Biodefense. Friedrich, B. M, C. E. Scully, J. M.

Brannan, Monica M. Ogg, S. C. Johnston, L. E. Hensley, G. G. Olinger, D. Smith.
December 2011.

77. Protective Role of Cytotoxic T Lymphocytes in Filovirus Hemorrhagic Fever. Warfield, K. L., G. G. Olinger. Journal of Biomedicine and Biotechnology Volume 2011, December 2011.
78. Enhanced Potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Zeitlin, L., J. Pettitt, N. Bohorova, D. Kim, M. Pauly, A. Hiatt, L. Ngo, H. Steinkellner, K. J. Whaley, G. G. Olinger. Proc. Natl Acad Science USA, December 20, 2011, 108 (51): 20690-4. doi:10.1155/2011/984241. Article ID 984241.
79. Real-time monitoring of cardiovascular function in rhesus macaques with Zaire ebolavirus. Kortepeter, M. G., J. V. Lawler, A. Honko, M. Bray, J. C. Johnson, B. K. Purcell, G. G. Olinger, R. Rivard, M. J. Hepburn, L. E. Hensley. Journal of Infectious Diseases, November 2011: 204; Suppl 3:1000-10.
80. Hexamminecobalt (III) Chloride As a Broad Spectrum Antiviral Complex. Chang, E. L., G. G. Olinger, L. E. Hensley, C. M. Lear, C. E. Scully, et al. J Antivir Antiretrovir 3: 020027. doi:10.4172/jaa.1000030, 2011.
81. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Sullivan, N. J., L. Hensley, C. Asiedu, T. W. Geisbert, D. Stanley, J. Johnson, A. Honko, G. Olinger, M. Bailey, J. B. Geisbert, K. A. Reimann, S. Rao, M. Roederer, P. B. Jahrling, R. A. Koup, G. J. Nabel. Nature Medicine, doi:10.1038/nm.2447, August 21, 2011.
82. High-dose mannose-binding lectin therapy for ebola virus infection. Michelow, I. C., C. Lear, C. Scully, L. I. Prugar, C. B. Longley, L. M. Yantosca, X. Ji, M. Karpel, M. Brudner, K. Takahashi, G. T. Spear, R. A. Ezekowitz, E. V. Schmidt, G. G. Olinger. J Infect Dis., 203(2): 175-9, January 2011.
83. A Novel L-Ficolin/Mannose-Binding Lectin Chimeric Molecule with Enhanced Activity Against Ebola virus. Michelow, I. C., M. Dong, B. A. Mungall, L. M. Yantosca, C. M. Lear, X. Ji, M. Karpel, C. L. Rootes, M. Brudner, G. Houen, D. P. Eisen, T. B. Bernard Kinane, K. Takahashi, G. L. Stahl, G. G. Olinger, G. T. Spear, A. B. Ezekowitz, E. V. Schmidt. Journal of Biological Chemistry, In Press, August 2010.
84. Inhibition of Heat-Shock Protein 90 Reduces Ebola Virus Replication. Smith, D. R., S. McCarthy, A. Chrovian, G. G. Olinger, A. Stossel, T. W. Geisbert, L. E. Hensley, J. H. Connor. Antiviral Res., May 6, 2010.
85. Development of FGI-106 as a broad-spectrum therapeutic with activity against members of the family Bunyaviridae. Smith, D. R., M. Ogg, A. Garrison, A. Yunus, A. Honko, J. Johnson, G. Olinger, L. E. Hensley, M. S. Kinch. Virus Adaptation and Treatment, 2010: 2, 9-20.
86. Targeting Biodefense Markets, Human Vaccines. Olinger, G. G. Volume 5, Issue 10, October 2009, 660-665.

87. Zaire Ebola virus entry into human dendritic cells is insensitive to cathepsin L inhibition. Martinez, O., J. Johnson, B. Manicassamy, L. Rong, G. G. Olinger, L. E. Hensley, C. F. Basle. Cell Microbiol, September 22, 2009.
88. Discovery of common marburgvirus protective epitopes in a BALB/c mouse model. Kalina, W. V., K. L. Warfield, G. G. Olinger, A. Bavari. Virol J., August 27 2009, 6: 132.
89. FGI-104: a broad-spectrum small molecule inhibitor of viral infection. Kinch, M. S., A. S. Yunus, C. Lear, H. Mao, H. Chen, Z. Fesseha, G. Luo, E. A. Nelson, L. Li, Z. Huang, M. Murray, M. Y. Ellis, L. Hensley, J. Christopher-Hennings, G. G. Olinger, M. Goldblatt. American J. Translational Research, 2009; 1: 87-89.
90. Donor variability in HIV binding to peripheral blood mononuclear cells. Anzinger, J. J., G. G. Olinger, G. T. Spear. Virology Journal, August 15, 2008: 5(1): 95.
91. Filovirus-Like Particles Produced in Insect Cells: Immunogenicity and Protection in Rodents, Journal of Infectious Diseases. Warfield, K. L., D. A. Alves, S. B. Bradfute, D. K. Reed, S. VanTongeren, W. V. Kalina, G. G. Olinger, D. Esposito, W. K. Gillette, R. F. Hopkins, J. Costantino, R. G. Panchal, J. L. Hartley, J. M. Aman, S. Bavari. November 2007: 196 (Suppl 2) S421-S429.
92. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. Warfield, K. L., N. A. Posten, D. L. Swenson, G. G. Olinger, W. V. Kalina, J. M. Aman, S. Bavari. Journal of Infectious Diseases, November 2007: 196 (Suppl 2) S430-S437.
93. Development of a model for a model for Marburgvirus based on severe-combined immunodeficiency mice. Warfield, K. L., D. A. Alves, S. B. Bradfute, D. K. Reed, S. Vantongeren, W. V. Kalina, G. G. Olinger, S. Bavari. Journal of Virology, October 2007, 4; 108.
94. Ebola virus inactivation with preservation of antigenic and structural integrity by photoinducible alkylating agent. Warfield, K. L., D. L. Swenson, , W. V. Kalina, M. Viard, M. Aitichou, X. Chi, S. Ibrahim, R. Blumenthal, Y. Raviv, G. G. Olinger, S. Bavari, J. M. Aman. Journal of Infectious Diseases, November 2007: 196 (Suppl 2) S276-S283.
95. Filoviruses and the balance of innate, adaptive, and inflammatory responses. Mohamadzadeh, M., L. Chen, G. G. Olinger, W. D. Pratt, A. L. Schamaljohn. Viral Immunol., Winter 2006; 19(4): 602-12
96. Activation of triggering receptor expressed on myeloid cells-1 on human neutrophils by Marburg and Ebola viruses. Mohamadzadeh, M., S. S. Coberley, G. G. Olinger, W. V. Kalina, G. Ruthel, C. L. Fuller, D. L. Swenson, W. D. Pratt, D. B. Kuhns, A. L. Schamaljohn. J Virol., July 2006; 80(14): 7235-44.
97. Gene-Specific Countermeasures against Ebola Virus Based on Antisense Phosphorodiamidate Morpholino Oligomers. Warfield, K. L., D. L. Swenson, G. G.

Olinger, D. K. Nichols, W. D. Pratt, R. Blouch, D. A. Stein, M. J. Aman, P. L. Iversen, S. Bavari. PLoS Pathogen, January 13, 2006 13; 2(1).

98. Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteins. Olinger, G. G., R. J. Hogan, M. A. Bailey, R. Bakken, A. Kuehne, M. K. Hart. Journal of Virology, November 2005; 79(22): 14189-96.
99. Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. Warfield, K. L., G. G. Olinger, E. M. Deal, D. L. Swenson, M. Bailey, D. L. Negley, M. K. Hart, S. Bavari. Journal of Immunology, July 15, 2005; 175 (2), 1184-91.
100. Mannose-binding lectin binds to Ebola and Marburg envelope glycoproteins, resulting in blocking of virus interaction with DC-SIGN and complement-mediated virus neutralization. Xin, J., G. G. Olinger, S. Aris, Y. Chen, H. Gewurz, G. T. Spear. Journal of General Virology, September 2005; 86(Pt 9): 2535-42.
101. Cellular factors influence the binding of HIV-1 primary isolates to primary cells, AIDS Res Hum Retroviruses. Olinger, G. G., M. L. Hart, M. Saifuddin, G. T. Spear. March 2002 18(4): 259-67.
102. The role of the complement system in virus infections. Spear, G. T., M. Hart, G. G. Olinger, F. B. Hashemi, M. Saifuddin. Curr Top Microbiol Immunol., 260:229-45, 2001.
103. Human antibodies to MHC alloantigens mediate lysis and neutralization of HIV-1 primary isolate virions in the presence of complement. Spear, G. T., G. G. Olinger, M. Saifuddin, H. M. Gebel. J Acquir Immune Defic Syndr, February 1, 2001; 26(2): 103-10.
104. CD-4 negative cells bind human immunodeficiency virus type-1 and efficiently transmit virus to T cells. Olinger, G. G., M. Saifuddin, G. T. Spear. Journal of Virology, September 2000, 74 (18): 8550-8557.
105. Alteration of complement protein levels after antiretroviral therapy in HIV-infected persons. Spear, G. T., G. G. Olinger, B. L. Sullivan, A. L. Landay, H. Kessler, E. Connick, D. Kuritzkes, M. St. Clair, J. Spritzler, H. Wu, M. M. Lederman, M. Saifuddin. AIDS Research and Human Retroviruses, December 10, 1999; 15 (18): 1713-1715.
106. Association of indicators of bacterial vaginosis with a female genital tract that induces expression of HIV-1, AIDS. Olinger, G. G., F. B. Hashemi, B. E. Sha, G. T. Spear. 13 (14): 1905-1912, October 1, 1999.
107. Vaginosis-associated microflora isolated from the female genital tract activates HIV-1 expression. Al-Harhi, L., K. A. Roebuck, G. G. Olinger, A. Landay, B. E. Sha, F. B. Hashemi, G. T. Spear. Bacterial Journal of Acquired Immune Deficiency Syndromes, 21(3): 194-202, July 1, 1999.
108. Characterization of protein 39 on the Lyme disease bacterium Borrelia burgdorferi. Olinger, G. G., R. E. Ratzlaff. Old Dominion University Honors Research Journal, Spring 1992.

B. OTHER:

Thesis/Dissertation

1. Ph.D. Dissertation: *Mechanisms of Attachment of HIV-1 to CD4 Positive Cells and the Role in Virus Infectivity*. Advisor Gregory T. Spear, Ph.D.
2. MBA Thesis: *A Business Perspective on the Decision to Manufacture a Pandemic H5N1 Influenza Vaccine or Therapeutic: Background Analysis for the Preparation of a Business Case*. Advisor Karl W. Einolf, PhD.

Proceedings and Symposia: N/A

Reviews: N/A

Book Chapters

1. Ebolavirus Kaplan, G; Olinger, G. G; Munir, M Mononegaviruses of veterinary importance. Volume I: Pathobiology and molecular diagnosis. 2013. p.224-247
2. Filoviruses Olinger, G.; Geisbert, T.W.; Hensley, L.E Encyclopedia of Virology. 2008. Vol.2, p.198-205
3. Nonhuman Primate Models of Ebola Virus Disease Richard S Bennett, Louis M Huzella, Peter B Jahrling, Laura Bollinger, Gene G Olinger Jr, Lisa E Hensley. Current topics in microbiology and immunology, 10.1007/82. 2017. 20 2017, Vol.411, p.171-193, Article 171
4. John Connor, Gary Kobinger, Gene Olinger. (2017). Therapeutics Against Filovirus Infection. Elke Mühlberger; Lisa L. Hensley; Jonathan S. Towner. Marburg- and Ebolaviruses: From ecosystems to molecules. (411): 263-290. <http://dx.doi.org/https://doi.org/10.1007/978-3-319-68948-7>. Co-Author. Published, Springer International Publishing AG, Cham, Switzerland.
5. Randal J. Shoepf, and Gene Olinger. Manual of Security Sensitive Microbes and Toxins, Filoviruses. 2014. United Kingdom: Taylor & Francis Group. <https://doi.org/10.1201/b16752> Chapter 7p. 65-80.
6. Laboratory Needs for Research Response Lisa E. Hensley, John D. Klena, Jason T. DeBoer, Joel M. Montgomery, Placide Mbala, Melissa E. Moses, Katie J. Knappek, Gene G. Olinger. Principles and Practice of Emergency Research Response. Publication September 4, 2024. Springer ISBN-10: 303148407X

Varia (online modules, CDs)

1. (2020). *COVID-19 Genomic Epidemiology Training Multisectoral partnership will deliver tools and expertise to identify and stop COVID-19 and other disease threats and strengthen leadership for health security in Africa. MRIGlobal supporting Africa Pathogen Genomics Initiative. Bill and Melinda Gates, Illumina and Microsoft. Virtual Training Module*

Abstracts: (Selected)

1. Mercury Laboratory: Bringing the Laboratory to the Sample Joe Bogan, Joseph Russell, Brittany Campos, Alex Boardmann, Jacob Aspinwall, Gene Ollinger One Health India Conference - New Delhi, India February 2019
2. Blended Learning Approach to Build Sustainable Wise Workforce: Social Media, Virtual & Augmented Reality Gene Ollinger, Kenny Yeh, Julia Michelotti, Debanjana Dasgupta, Joe Bogan One Health India Conference - New Delhi, India February 2019
3. Mobile Importance of Public and Private Partnerships for Enhancing Chemical and Biological Defense Capabilities Alex Terray, Kenneth Yeh, and Gene Ollinger Gordon Research Conference (GRC) on Chemical Biological Terrorism Threats March 2019
4. Biosecurity Readiness for a Non-proliferation Mission: Meeting Threat Reduction Resource Needs Yeh, Ollinger, Royse Health Emergencies: Preparedness & Management; Surveillance and outbreak response May 2019
5. Chicken and Egg; a Catch 22 Paradox for Surveillance and Control of Avian Influenza Julia Michelotti, Brian Backstedt, Lolly Gardiner, Julie Lucas, Gene Ollinger, and Kenny Yeh American Public Health Laboratory Conference June 2019
6. Engaging Latin American countries under the biological threat reduction and related global health security programs Kenny Yeh, Brooke Borgert, Gene Ollinger, Falgunee Parekh, and Jeanne Fair Global Health Security Conference June 2019
7. Biosecurity Readiness for a Non-proliferation Mission: Meeting Threat Reduction Resource Needs Kenny Yeh, Gene Ollinger, Chris Royse Global Health Security Conference June 2019
8. Microfluidics poster: Bridging the Valley of Death: Helping Laboratory R&D and Diagnostic Development Meet the Operational Demands at the Point of Need Alex Terray, Joseph Russell, Richard Winegar, Chris Detter, Kristine Werking, Gene Ollinger, Kenny Yeh, Richard Masino. Gordon Research Conference June 2019
9. Novel Approaches for Capture, Detection and Decontamination of Biological Agents Gene Ollinger and Lokesh Joshi DTRA - CBD S&T Conference November 2020
10. How to Validate an In Vitro Diagnostic Method with Limited access to Human Samples? the Complex Clinical Strategy for the ARad Biodosimetry System Michaela Hoffmeyer, Cynthia Zimmerman, Hillary Wood, Gene Ollinger, Kristine Werking September 2020
11. A High Quality, Hybrid Whole Genome Sequencing and Analysis Pipeline for Characterization of Resistance Profiles in Mycobacterium tuberculosis Ryan Howard, David Yarmosh, Derek Armstrong, Nikki Parish, John Bagnoli, Gene Ollinger, Alex Terray, Jonathan Jacobs, Erin Tacheney APHL Virtual Conference September 2020

12. High-quality, Hybrid Whole Genome Sequencing and Analysis Pipeline for Characterization of Resistance Profiles in Mycobacterium Tuberculosis R. Howard, D. Yarmosh, D. T. Armstrong, N.M. Parrish, J. Bagnoli, G. Olinger, A.V. Terray, E.A. Tacheny Sequencing, Finishing, and Analysis in the future (SFAF) Conference, New Mexico. December 2021.
13. Antibiotic Resistance Profile Determination Using Whole Genome Sequencing Ryan Howard, Dave Yarmosh, D. Armstrong, N Parrish, John Bagnoli, Gene Olinger, A Terray and Erin Tacheny 51th Union World Conference on Lung Health TB Science 2020 Conference December 2021.
14. Evaluation of a targeted next-generation sequencing diagnostics assay for identification of M. Tuberculosis and non-tuberculosis mycobacteria isolates M. Megan Lemmon, Ryan Howard, Molly Lumnitzer, Debanjana Dasgupta, Gene Olinger, Erin Tacheny National Tuberculosis Controllers Association: 2021 National TB Conference July 2021.
15. When There is a Will, There is a Way: Evolution of Ebola Diagnostics During the 2014-2016 West African Outbreak Gene Olinger International Conference on Emerging Infectious Diseases (ICEID) Argentina August 2018.
16. Building Social Networks for Sustainable Local Outbreak Response Capabilities. J. Michelotti, D. Dasgupta, and G. Olinger American Public Health Laboratory (APHL) Annual Conference June 2018
17. Establishment and Use of Field Forward Diagnostic Laboratories and Assays for Viral Pathogens During Outbreaks G. Olinger, L. Presser, A. Parsons, M. Adams, P. Matero, D. Roberts, K. Yeh ASM Clinical Virology Symposium (CVS) May 2018
18. When There is a Will, There is a Way: Evolution of Ebola Diagnostics During the 2014-2016 West African Outbreak G. Olinger, H. Wood, L. Presser, K. Yeh, J. Michelotti, D. Roberts, J. Coffin ASM Clinical Virology Symposium (CVS) May 2018

Papers and Continuing Education Programs Presented: N/A

PUBLICATIONS – IN PRESS:

None at this time.

INVITED LECTURES AT SYMPOSIA AND CONFERENCES:

1. (2024) When There is a Will, There is a Way: Evolution of Ebola Outbreak Response. 83rd National Environmental Health Association (NEHA) Annual Educational Conference & Exhibition 2019. Nashville, TN. Main Audience: Scientist, Public, Decision Maker

2. (2024) Chesapeake Area Biological Safety Association Hybrid Technical Seminar. *Emerging Infectious Diseases*. Main Audience: Researcher
3. (2023) *Marburg virus and lessons learned during the West Africa Ebola outbreak*. Outbreak News TV. Main Audience: Public
4. (2023) BARDA Industry Day Division of Nonclinical Development (DNCD) Panel Discussion on *Nonclinical Models for Product Development and Advancement to Licensure: What's in the Toolbox?* Main Audience: Researcher
5. (2023) Front Range Biological Association (FrABSA) Virtual Seminar *Update on Respiratory Pathogens*. Main Audience: Researcher
6. (2023) National Bio and Agro-Defense Facility (NBAF) USDA Lunch & Learn Seminar: *Journey thru the history of vaccines*. Main Audience: Researcher
7. (2023) National Bio and Agro-Defense Facility (NBAF) USDA Technical Seminar: *Data Management*. Main Audience: Researcher
8. (2023) National Bio and Agro-Defense Facility (NBAF) USDA Technical Seminar: *Ethics in Science*. Main Audience: Researcher
9. (2023) Sierra Leone Njala University Technical Consultant Expert Mission International Atomic Energy Agency Animal Production and Health Section Joint FAO/IAEA Centre of Nuclear Techniques in Food and Agriculture RAF5089 “Strengthening the Capacities of National Veterinary Laboratories for the Early Warning, Control and Prevention of Outbreaks of Animal and Zoonotic Diseases (AFRA) Main Audience: Scientist Researcher
10. (2023) The Anima Health Laboratory, Division of Veterinarian Services, Ministry of Agro Industries and Fisheries. Reduit, Mauritius. Sierra Leone Njala University Technical Consultant Expert Mission International Atomic Energy Agency Animal Production and Health Section Joint FAO/IAEA Centre of Nuclear Techniques in Food and Agriculture RAF5089 “Strengthening the Capacities of National Veterinary Laboratories for the Early Warning, Control and Prevention of Outbreaks of Animal and Zoonotic Diseases (AFRA) Main Audience: Scientist Researcher
11. (2023) Washington DC Public Health Laboratory Seminar Series, invited speaker *Global health and infectious disease*. Main Audience: Researcher
12. (10/2022) Geospatial Information and Biosecurity Cross-Talk: Addressing the gaps and shortfalls. Presenter and Panelist. Main Audience: Researcher
13. (2022): New England Biosafety Association NEBSA Quarterly Webinar Series: *Rethinking Laboratory Training to Achieve Optimal Competency and Proficiency* (virtual) Main Audience: Researcher
14. (2022) H3D Delegates 3rd H3D SYMPOSIUM 2022 - Academic programme University of Cape Town Main Audience: Scientist Researcher

15. (2022) Sequencing to Function: Analysis and Application for the Future (SFAF) Science Talk *Development of Cutaneous Microbiome in Minipig Model for treatments and wound healing*. Main Audience: Researcher
16. (2022) Hood College Seminar Series *Development of Medical Countermeasures for Highly Lethal Pathogens*. Main Audience: Researcher & Public
17. (2020) Challenges facing COVID-19 selection and vaccination at the 11th Annual KAIMRC Global Forum G20 event entitled COVID-19 Vaccines: Global Challenges and Prospects, <https://globalcovid19vaccines.com>. Co-organizer
18. (2020) *Pandemic Response: Focus on emerging viruses*. Scientist Spotlight, MRIGlobal. Main Audience: Public
19. (2020) *Is COVID-19 a Warning Call?* MRIGlobal. Main Audience: Public
20. (2008) Gabon Libreville, Gabon, Antiviral Discovery and Synergistic Combinations. Main Audience: Scientist Researcher
21. (2006) Winnipeg Manitoba, Filovirus Symposium Public Health Agency of Canada International Centre for Infectious Diseases. VEE replicon Vaccine for Filoviruses. Main Audience: Scientist Researcher
22. (2019) Global Health Security Conference - The Inaugural Global Health Security Conference took place at the International Convention Centre, Sydney. Public Partnership to Develop Ebola Antibody Treatment. Main Audience: Scientist Researcher
23. (2018) 9th Advanced Course on Diagnostics (ACDx) Fondation Mérieux, *Regulatory Pathway for Diagnostics*. Main Audience: Researcher
24. (2018) CaliConf Cali, Valle del Cauca, Colombia Panel: Rapid Response of Emerging Trends How to Build Capacity in an Interconnected World. Main Audience: Scientist Researcher/ Decision Maker
25. (2015): NIH, NIAID DCR Serology Team in Liberia. Liberian Institute for Biomedical Research (LIBR) Partners Symposium. Workshop co-chair and speaker. Monrovia, Liberia. Main Audience: Researcher
26. (2015) Therapeutic, Vaccines and Animal models utilizing medical imaging. *MERS-CoV Research Initiative Workshop*, King Saud bin Abdulaziz University for Health Sciences, and the King Abdullah International Research Center with the collaboration of the Ministry of National Guard Health Affairs, the Ministry of Health, and the Saudi Food and Drug Authority. Invited speaker and attendee. Riyadh, KSA. Main Audience: Researcher
27. (2015) Development of a monoclonal antibody cocktail for Ebola virus therapy: convergence of plants, mice, and humans. Mastering Immunity 5. Invited committee member and speaker, British Consulate-General, Cambridge, MA. USA. Main Audience: Researcher
28. (2015) Development of Passive Immunity for Ebola Virus Infections Through Convergence of Science & Technology: Mice, Primates, and Plants. Moving Targets

2015, Breakthrough Therapies in Immunology. Session II: Global Health and Infectious Diseases. Invited speaker, panelist. Los Angeles, CA, USA. Main Audience: Researcher

29. (2015): Outbreaks and lessons learned from an on-going global emergency. National Interagency Confederation for Biological Research (NICBR) Summer Student Seminar Series. Speaker. Frederick, MD, USA. Main Audience: Researcher
30. (2015): Development of a monoclonal antibody cocktail for Ebola virus therapy: convergence of plants, mice, and humans. Global Technology Community (GTC) Infectious World Disease Summit. Plenary Session, Special Topics: Lessons Learned from the 2014 Ebola Outbreak. Featured speaker and attendee. Boston, MA, USA. Main Audience: Researcher
31. (2015) Biosafety 4 laboratories in the USA and in the field. UTMB and FDA, Achieving Data Quality and Integrity in Maximum Containment Laboratories Course. Faculty. Natcher Conference Center on the campus of the National Institutes of Health (NIH) in Bethesda, MD, USA. Main Audience: Researcher
32. (2015) Development of Passive Immunity for Ebola Virus Infections Through Convergence of Science & Technology: Mice, Primates, and Plants. Northern California Regional Chapter of the Society of Toxicology (NorCal SOT) Spring Symposium Preclinical Drug Development, Biothreats, and Biomarkers of Toxicity. Keynote Speaker. South San Francisco Conference Center, South San Francisco, CA, USA. Main Audience: Researcher
33. (2015) Disruptive Innovation to Accelerate Discovery. Leaders of Tomorrow Summit Panelist and speaker. Gaithersburg, MD. USA. Main Audience: Researcher/Public
34. (2015) Role of antibodies: Passive transfer in NHPs and humans, and summary of ZMapp, Update of medical research on monoclonal antibody therapy of Ebola, International Conference on Scientific Insight and Response of Ebola Virus Disease. Invited participant and speaker, Beijing, China. Main Audience: Researcher
35. (2015) Session IV, Clinical Characteristics and Treatment of EVD, Session Co-Chair, International Conference on Scientific Insight and Response of Ebola Virus Disease, Beijing, China. Main Audience: Researcher
36. (2015) Identifying Vaccines and Therapeutics for Viral Biothreat Infections. Chemical & Biological Terrorism Defense: Research Synergies for Chemical and Biological Defense. Gordon Research Conference. Invited participant and speaker, Ventura, CA, USA. Main Audience: Researcher
37. (2015) In vitro Evaluation of Repurposed and Fast Track Drugs for EVD: an accelerated drug discovery pipeline. World Health Organization (WHO) Science Therapeutic Antiviral Committee (STAC). Invited participant and speaker, Montreux, Switzerland. Main Audience: Researcher
38. (2015) Diagnostics, Sequencing and Emerging Technologies for Ebola Virus. World Health Organization (WHO) Ebola Science Committee: Prioritization of Research Agenda. Invited participant and speaker, Montreux, Switzerland. Main Audience: Researcher

39. (2015) Science and humanity fight a virus in a distant land. Rotary International, Maryland Chapter. World Peace and Understanding Exposition, *Health as a Bridge to Peace: Rotary Responds to the Ebola Outbreak*. Invited keynote speaker. Jack B. Kussmaul Theater Arts Center, Frederick Community College Frederick, MD. Main Audience: Researcher
40. (2015) How can you help fight Ebola in Western Africa. Carroll Creek Rotary International Monthly meeting. Invited speaker. Frederick, MD. Main Audience: Researcher
41. (2015): Animal models for EVD and their comparison to human disease. World Health Organization (WHO) Clinical Aspects of the Ebola Virus Disease. Invited participant and speaker, Foundation Louis-Jeantet, Auditoire Louis-Jeantet, Geneva, Switzerland. Main Audience: Researcher
42. (2014) 6th International Filovirus Meeting, Galveston, Texas, Main Audience: Scientist Researcher
43. (2014) Converging science disciplines and search for medical solutions to protect against viral hemorrhagic fever viruses. Department of Microbiology & Immunology, Rush University and University of Chicago Illinois Seminar Series. Invited speaker. Chicago, IL. Main Audience: Researcher
44. (2014) Can we predict outbreaks, when we don't listen to the data. Engaging Scientific Collections in Emerging Infectious Disease Research, Speaker, panelist and workshop attendee. Scientific Collections International (SciColl). Smithsonian Institution's National Museum of Natural History in Washington, DC. Main Audience: Researcher
45. (2014) Development of Passive Immunity for Ebola Virus Infections Through Convergence of Science & Technology: Mice, Primates, and Plants. Biodefense Seminar Series, University of Virginia. Invited speaker. Charlottesville, VA. Main Audience: Researcher
46. (2014) Converging science disciplines and search for medical solutions to protect against viral hemorrhagic fever viruses. MIC, Department of Microbiology, Immunology and Cancer Biology Seminar Series, University of Virginia. Invited speaker. Charlottesville, VA. Main Audience: Researcher
47. (2014) Converging science disciplines and search for medical solutions to protect against viral hemorrhagic fever viruses. U.S. Army National Ground Intelligence Center. Invited speaker. Charlottesville, VA. Main Audience: Researcher/Decision Maker

INVITED LECTURES – OFF CAMPUS:

See above.

GENERAL COMMUNICATIONS (e.g. article quotes, podcasts, blogs):

1. Working with Marburg in the Lab: An Investigator Explains. Global Center for Health Security UNMC <https://www.unmc.edu/healthsecurity/transmission/2023/04/18/working-with-marburg-in-the-lab-an-investigator-explains/> (April 18 ,2023)
2. 14 Ways Entrepreneurs Can Make Sure Business Investors Feel Heard and Happy News Week Expert Panel (November 9, 2023)
3. 15 Ways to Encourage Respectful Debate in the Workplace News Week Expert Panel (October 9, 2023)
4. Malaria: Experts Answer Questions for Infection Prevention Personnel infectioncontroltoday.com (Aug. 1, 2023)
5. Marburg virus and lessons learned during the West Africa Ebola outbreak via Outbreak News TV: <https://www.youtube.com/watch?v=8535sYEJUM> (May 12, 2023)
6. Living Better Than the Jetsons: Six Science and Technology Innovations That Will Transform Your Life in the Next Five Years News Week Article (April 25, 2023)
7. Working With Marburg in the Lab: An Investigator Explains infectioncontroltoday.com (April 17, 2023)
8. 15 Ways Businesses Can Keep Up With Trends in the Tech World Expert Panel (March 16, 2023)
9. What Are the First Symptoms of Monkeypox? - Parade (Aug. 1, 2022)
10. Kansas reports first case of monkeypox; BA.5 variant of COVID-19 highly infectious | KCUR - Kansas City news and NPR (July 12, 2022)
11. March could see vaccine for children under 5 years old | KCUR - Kansas City news and NPR (Jan. 28, 2022)
12. Kansas City won't escape omicron, COVID-19's newest variant | KCUR - Kansas City news and NPR (Dec. 7, 2021)
13. SARS-COV 2 Identikit di un killer (Identikit of a killer) Italian Tv News <https://www.raiplay.it/video/2020/11/SARS-COV2---Identikit-di-un-Killer-f4b539cc-07ac-41c2-a1a4-1aab862f75ff.html> (November 2021)
14. Gene Olinger joins Fault Lines to Discuss the Covid Boosters Fault Lines Radio <https://www.youtube.com/watch?v=pGCRcSf-Khg> (September 2021)
15. Mandates and COVID Politics; Assange Witness Fabrications; Remote Learning and Special Needs Political Misfits - YouTube <https://www.youtube.com/watch?v=hWeZjQGnlbc&t=1262s> (September 2021)
16. Delta Variants spread: Pandemic Highlights Inequities KCUR Kansas NPR <https://www.kcur.org/podcast/up-to-date/2021-08-18/clearing-the-confusion-about-covid-9-boosters> (August 18, 2021)

17. Clearing The Confusion About COVID-19 Boosters | KCUR - Kansas City news and NPR (Aug. 18, 2021)
18. Delta Variant Flourishes As Vaccination Rates Stagnate | KCUR - Kansas City news and NPR (July 29, 2021)
19. Delta Variant Flourishes as vaccination rates stagnate Up to Date Segment KCUR 89.3 NPR Kansas City. <https://www.kcur.org/podcast/up-to-date/2021-06-29/delta-variant-flourishes-as-vaccination-rates-stagnate> (June 29, 2021)
20. Gene Olinger Joins Fault Lines to Discuss the Delta Variant and Covid's Next Surge YouTube video - Fault Lines Radio <https://www.youtube.com/watch?v=m7Pb4Ej9A00> (July 2021)
21. Delta Variant Spreads | Pandemic Highlights Inequities | KCUR - Kansas City news and NPR (June 29, 2021)
22. MRIGlobal Experts Co-Author Article Examining Need for Greater Global Health Security Investment in Latin America PRNewswire.com <https://www.prnewswire.com/news-releases/mriglobal-experts-co-author-article-examining-need-for-greater-global-health-security-investment-in-latin-america-301313032.html> (June 15, 2021)
23. A Viral Story About A Kansas Woman's Death Is A Case Study In Vaccine Misinformation | KCUR - Kansas City news and NPR (March 30, 2021)
24. Cause of Death Not verified/Kansas City Gyms Get Creative Gene Olinger KCUR 89.3 NPR Kansas City <https://www.kcur.org/2021-03-29/cause-of-death-not-verified-kansas-city-gyms-get-creative> (March 29, 2021)
25. MRIGlobal Virologists and Infectious Disease Experts Partner with Kansas City University Gene Olinger, Carl Gelhaus, Shelton Bradrick KC Animal Health <https://kcanimalhealth.thinkkc.com/news/news-releases/2021/03/12/mriglobal-virologists-and-infectious-disease-experts-partner-with-kansas-city-university> (March 12, 2021)
26. New COVID-19 Variants Found in Kansas City Area KCUR 89.3 NPR Kansas City. <https://www.kcur.org/podcast/up-to-date/2021-03-04/new-covid-19-variants-found-in-kansas-city-area> (March 4, 2021)
27. New COVID-19 Variants Found In Kansas City Area | KCUR - Kansas City news and NPR (March 4, 2021)
28. COVID 19 variants Update KCUR 89.3 NPR Kansas City COVID-19 Variants Update (March 2, 2021)
29. Virtual Stem Event: The Hot Zone - a true account of the Ebola Outbreak in Reston VA in the early '90s Virginia Governor's Junior High School Class (March 2021)

30. Preeminent Scientists from MRIGlobal to Join KCU as faculty Kansas City University
<https://www.kansascity.edu/blog/news-releases/preeminent-scientists-from-mriglobal-join-kcu-as-faculty> (February 15, 2021)
31. MRIGlobal Scientists Co-Authors Research that looks at New Approach to Treating Virus Outbreak
https://www.prnewswire.com/news-releases/mriglobal-scientist-co-authors-research-that-looks-at-new-approach-to-treating-virus-outbreaks-301215943.html?tc=eml_cleartime (January 27, 2021)
32. Missouri just topped 400,00 coronavirus cases and a new strain of the coronavirus is being reported in the United Kingdom, but experts remain optimistic about vaccines
KCUR 89.3 NPR Kansas City <https://www.kcur.org/podcast/up-to-date/2021-01-04/your-questions-about-the-coronavirus-vaccine-answered> (January 4, 2021)
33. Your Questions About The Coronavirus Vaccine Answered | KCUR - Kansas City news and NPR (Jan. 4, 2021)
34. MRIGlobal Scientists Co-Authors Research that looks at New Approach to Treating Virus Outbreak
https://www.tribuneledgernews.com/extra/news/mriglobal-scientist-co-authors-research-that-looks-at-new-approach-to-treating-virus-outbreaks/article_25364b2f-dcf2-5535-b7d3-732c6faf7402.html (January 2021)
35. Research develop artificial intelligence platform to combat infectious diseases
Expresscomputer.com/news <https://www.expresscomputer.in/news/researchers-develop-artificial-intelligence-platform-to-combat-infectious-diseases/63455/> (September 11, 2020)
36. New cellular pathway protects cells from infection by Ebola virus, coronaviruses News Medical Life Sciences <https://www.news-medical.net/news/20200828/New-cellular-pathway-protects-cells-from-infection-by-Ebola-virus-and-coronaviruses.aspx> (August 28, 2020)
37. Yes, Cleaning Surfaces will still help you fight the Coronavirus Up to Date Segment KCUR 89.3 NPR Kansas City. <https://www.kcur.org/podcast/up-to-date/2020-08-24/yes-cleaning-surfaces-will-still-help-you-fight-the-coronavirus> (August 24, 2020)
38. Novel protection pathway makes cells resistance to Ebola and coronavirus infection, report scientists Drug Target Review <https://www.drugtargetreview.com/news/69717/novel-protection-pathway-makes-cells-resistant-to-ebola-and-coronavirus-infection-report-scientists/> (August 28, 2020)
39. Discovery illustrated better understanding of cellular mechanisms involved in viral resistance Medical X Press <https://medicalxpress.com/news/2020-08-discovery-cellular-mechanisms-involved-viral.html> (August 27, 2020)
40. MHC Class II transactivator CIITA induces cell resistance to Ebola virus and SARS like coronaviruses EurekaAlert https://eurekaalert.org/pub_releases/2020-08/bri-mci082620.php (August 27, 2020)

41. Researchers discovers new avenue for fighting COVID-19, Ebola and other viral diseases. Geek Wire <https://www.geekwire.com/2020/researchers-discover-new-avenue-fighting-covid-19-ebola-viral-diseases/> (August 27, 2020)
42. As More People Go Back to Work, Kansas City Bus Drivers are New "Front Line Workers" Fighting COVID-19 Kansas NPR KCUR.ORG <https://www.kcur.org/community/2020-05-20/as-more-people-go-back-to-work-kansas-city-bus-drivers-are-new-front-line-workers-fighting-covid-19> (May 20, 2020)
43. Where did the Coronavirus come from? Past outbreaks provide hints NBCnews.com <https://www.nbcnews.com/science/science-news/where-did-new-coronavirus-come-past-outbreaks-provide-hints-n1144521> (May 6, 2020)
44. Corona Virus - Q&A Quora (April 2020)
45. Alumni Fighting COVID-19 on the Front Old Dominion University Discover Monarch Science Monarch Science Observer <https://www.odu.edu/content/dam/odu/col-dept/sci/docs/cos-april-spring-newsletter-2020.pdf> (April 2020).
46. What Everyone should know about vaccine development Forbes.com <https://www.forbes.com/sites/quora/2020/03/30/what-everyone-should-know-about-vaccine-development/#7c4456aec74a> (March 30, 2020).
47. What is the coronavirus survival rate? - Los Angeles Times (latimes.com) (March 19, 2020)
48. Seg. 1 : Coronavirus 101: Seg. 2 Coronavirus News Literacy: Understanding the basics of what virus is. Up to date radio KCUR Kansas NPR <https://www.kcur.org/show/up-to-date/2020-03-16/seg-1-coronavirus-101-seg-2-coronavirus-news-literacy> (March 16, 2020)
49. Coronavirus vs the human immune system: the brutal microscopic war for survival - TODAY (todayonline.com) (March 15, 2020)
50. MRIGlobal gathers experts for coronavirus Q&A on Reddit KC Business Journal <https://www.bizjournals.com/kansascity/news/2020/03/04/coronavirus-mriglobal-reddit-ama.html> (March 4, 2020)
51. Reddit session on COVID-19: We are researchers at MRIGlobal developing testing methods & biosafety procedures for COVID-19 & will test the efficacy of the vaccine. AUA! : IAmA (reddit.com) (March 4, 2020)
52. SARS-CoV/COVID-19 Gene Olinger Virology 101 News Literacy & Pandemics Radio <https://www.kcur.org/programs/date#stream/0> (March 2020)
53. The U.S. Government is Sharing its Test for the New Coronavirus NPR Nnews <https://www.npr.org/2020/02/05/803183336/the-u-s-government-is-sharing-its-test-for-the-new-coronavirus> (February 5, 2020)
54. Drug saves monkeys from close relative of Ebola | Nature (Aug. 20, 2014)

55. BU Scientist uses existing drugs in fight against Ebola Boston Globe
<https://www.bostonglobe.com/metro/2015/06/03/could-antidepressant-heart-drug-treat-ebola/WtHr5BnvMnjhSAVTZt1HdO/story.html> (June 4, 2015)
56. Ebola crisis: What is the experimental treatment ZMapp and will it be used to combat the virus outbreak in West Africa? - ABC News (Aug. 13, 2014)
57. MRIGlobal Blogs
- Mpox Becomes a Public Health Emergency - MRIGlobal (Aug. 5, 2022)
 - Should We “Beware the Kraken,” New COVID-19 Variant? - MRIGlobal (Jan. 6, 2023)
 - Why Are Eggs So Expensive? - MRIGlobal (Feb. 15, 2023)
 - Should I Be Worried About the Marburg Virus? - MRIGlobal (Feb. 22, 2023)
 - Malaria Finds its Way to the U.S. Again - MRIGlobal (Sept. 5, 2023)
 - New Infectious Disease Outbreaks Around the Holidays - MRIGlobal (Dec. 18, 2023)

I have read and take responsibility for the information in this document.

_____ Signature <i>(Signature required for SOM APT purposes only)</i>	_____ Date
---	---------------

APPROVED COD: May 2024